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.. SYNOPSIS 
21-hydroxylase deficiency is the commonest enzyme 
defect in congenital adrenal hyperplasia resulting in low 
ci rcula.ting cortisol and, in severe cases, low aldosterone 
which may lead to cardiac arrest in the neonate. As the 
low levels of coitisol· lead to raised levels of 
adrenocorticotrophic hormone large concentrations of 
androgens are formed in utero which may lead to 
cliteromegaly and consequent confusion of the sexes at 
bi rth. High concentrations of the androgens give rise to 
rapid growth in early childhood and early fusion of the 
epiphyses results in short stature of the adult. 
17-alphahydroxyprogesterone (170HP) is raised in the 
blood and saliva of children with 21-hydroxylase 
deficiency. 170HP is commonly measured by rad ioimmunoassay 
which limits the assay to being performed by laboratories 
equipped with beta or gamma counters. 
The aim of this project was to 
enzymeimmunoassay which coule be carried 
oevelop an 
out using the 
minimum amount of equipment. Horseradish peroxidase was 
con jugated to 170HP-O-ca.rboxymethyloxime usi ng a mi xed 
anhydride reaction. Separation of free and bound label 
was achieved using a second antibody linked to 
magnetisable particle solid phase. Measurement of the 
bound enzyme activity yielded colours which could be 
compared by eye, with known standards, to give a 
semi-quantitative assay. Alternatively the absorbance 
could be measured using a spectrophotometer for full 
quantitative results. 
The developed 
the results with 
measuring 170HP in 
situations. 
assays were evaluated, 
radioimmunoassay, and then 
blood and saliva in various 
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clinical 
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STEROID NormNCLJ\TURF. J\ND TRIVIAL NJ\I1ES 
Steroid nomenclature is as recommended by IUPAC-IUB 
Commission on Biochemical Nomenclature, Biochemical 
Journal (1969) 113 5 -28 
The following trivial names have been used: 
ll-deoxycortisol 
17-alphahydroxyprogesterone 
Androstenedione 
Cortisol 
Oestradiol 
Progesterone 
Testosterone 
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17~,21-trihydroxy-
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11,,8,170(, 21-t ri hyc1 roxy-
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.1,3,5(10)-oestratriene-3, 
17f-triol 
4-pregnene-3,20-c1ione 
17-hydroxy-4-androsten-
3-one 
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CHAPTER 1 
INTRODUCTION 
1.1 HISTORICAL BACKGROUND 
Congenital adrenal hyperplasia (CAR) is one of many 
recognised hereditable inborn errors of metabolism. The 
condition is associated with a deficiency. in one of the 
enzymes in the biosynthetic pathway from cholesterol to 
cortisol, which takes place in the adrenal. Since some 
forms of the disorder give rise to increased levels of 
androgen synthesis and changes in the genitals the 
condition has been referred to as the adrenogenital 
syndrome. However this name is no longer favoured and the 
term CAH will be used throughout this thesis. 
de Crecchio reporting on a post mortem he carried out 
in 1885 noted that the body had the external genitalia of 
a male but on dissection had a normal female vagina, 
uterus, fallopian tubes and ovaries. In addition he found 
the adrenal glands to be very much enlarged. The sex of 
the subject had been unclear at birth and had not been 
pronounced male until 4 years of age. For this description 
de Crecchio is regarded as having been the first to 
recognise the condition of CAH. 
Butler et al (1939) described, in detail, 
followed from 2 weeks of age to 20 months. 
an infant 
They found 
marked pigmentation around the areolae of the nipples and 
genitals with persistent low plasma sodium and high 
potassium but with high urinary sodium concentrations. 
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Unless the patient was given sodium supplements to the 
diet or adrenal extract he was found to vomit and 
develop listlessness which progressed to total collapse. 
They noted that the patient had a particularly well 
developed penis for his age and the urinary excretion of 
oestrogens and androgens was high. They suggested that 
the condition might be associated with hyperplasia of the 
adrenal cortex. 
Bartter et al (1951 ) described 3 girls who had first 
presented between the ages of 5 and 8 years with 
cliteromegaly and pubic hair who were subsequently 
followed up at 10 to 13 years when two of them had 
epiphyseal closure and all had markedly increased bone 
age, hirsuitism on the face and body and varying degrees 
of virilism. By measuring steroid metabolites in 24 hour 
collections of urine they were able to establish that the 
output of glucocorticoids was low, in contrast to that of 
androgens which were markedly raised. They then postulated 
that the administration of cortisone should suppress the 
production of adrenocorticotrophic hormone (ACTH) and 
consequently reduce adrenal androgen production. 
To one patient they administered ACTH alone and also 
in combination with cortisone. The results supported their 
previously held view that cortisol acts by inhibiting 
endogenous ACTH rather than by having a direct effect on 
the synthesis of androgens in the adrenal cortex. They 
further postulated that the primary defect in CAH was the 
decreased production of cortisol by the adrenal cortex in 
response to ACTH leading to an increased output of adrenal 
androgen from metabolism of the accumulated precursors of 
2 
cortisol. Administrat~on of cortisone acetate to 2 
patients at dosages of 100 and 200 mg a week reduced the 
17-oxosteroids, metabolites of androgens, to 'normal'. 
Earrter's hypothesis was later 
Bongiovanni et al (1954a) who found that 
of pregnanetriol (P-TRIOL) was raised 
confi rmed by 
the concentration 
in the urine of 
children with CAH and that this output was suppressed on 
the administration of cortisone therapy. They also 
established that P-TRIOL was the urine metabolite of 
17-alphahydroxyprogesterone (170HP). 
1.2 STEROID HORMONES 
The steroids are a group of compounds containing 
the perhydrocyclopentenophenanthrene nucleus. 
12 17 
16 
2 
15 
3 
of naturally They include a wide 
compounds among which are 
adrenocortical hormones, 
range 
the sterols, sex 
occurring 
hormones, 
alkaloids and other minor 
cardiac 
groups. 
glycosides, 
The general 
some 
name 
'steroid' was introduced in 1936 to cover all compounds 
3 
with the sterol-like skeleton. During the 1930's and 
1940's the basic chemistry of nearly all the known 
naturally occurring groups of steroids was determined. The 
structures of the sex hormones (oestrone, androstenedione, 
testosterone and progesterone) were described and methods 
of preparation of these compounds, from the cheap and 
accessible cholesterol, were developed. The structures of 
the hormones of the adrenal cortex, and many related 
inactive compounds were also described. 
In the intervening years there has been an increasing 
demand for cortisone and more potent synthetic stercids 
such as prednisolone which has 4 times the potency of 
cortisol. These steroids have been used extensively in the 
treatment of inflammatory disorders. 
1.3 BIOSYNTHESIS OF STEROID HORMONES 
The adrenal synthesizes 3 main classes of steroids; 
mineralocorticoids, glucocorticoids and sex steroids. 
Corticotrophin releasing factor from the hypo thalamus acts 
on the anterior lobe of the pituitary to release ACTH and 
this in turn acts on the adrenals to increase the 
conversion of cholesterol to pregnenolone, the principle 
substrate for all the pathways in steroid synthesis. The 
biosynthesis of steroid hormones in man is shown in 
Figure 1. 
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1.4 FOETAL SEXUAL DEVELOPMENT 
The presentation of an infant with CAR at birth is 
affected by the increased levels of androgens in utero. In 
the case of a genetically male foetus the undifferentiated 
gonad secretes the androgen testosterone (T) which 
stimulates the wolffian ducts to develop into the male 
internal genitalia. 5-alpha-reductase reduces T to 
dihydrotestosterone (DRT) in the target tissue and this 
androgen induces differentiation of the male external 
genitalia. The normal source of T in the male is the 
foetal testis but androgens from the adrenal or from 
medication administered to the mother may result in 
masculinisation of the external genitalia. The testes 
also secret~ mullerian inhibitory factor (rUF) , a 
non-steroidal substance, which inhibits development of 
the female external genitalia (mullerian ducts) enabling 
the normal male to be born without a uterus. 
The foetal ovary does not secrete T or ~IF and 
consequent ly the normal female is born without male 
external genitalia but with mullerian development into the 
uterus and fallopian tubes. Female foetuses exposed to 
high levels of androgen due to an enzyme deficiency, as in 
CAR, or an androgen producing tumour in the mother, or to 
maternal ingestion of androgens will 
virilisation of the external genitalia. 
1.5 ENZYME DEFECTS IN CAR 
The most common enzyme deficiency 
(210Rase) which is responsible for 90 -
diagnosed CAR. 11-hydroxylase ( 11 OHase) 
6 
manifest as 
is 21-hydroxylase 
95% of cases of 
accounts for a 
further 5 to 8% and 17-hydroxylase (170Hase), 
3-beta-hydroxysteroid dehydrogenase (3-beta-HSD) and other 
enzymes of the pathway for less than 1% (White et al (1987 
a & b». 
DEFICIENCY OF 3-BETA-HSD 
In this disorder levels of 17-hydroxypregnenolone and 
dehydroepiandrosterone (DHA) are elevated but the DHA is 
not converted to androstenedione (A4) or T. The raised 
levels of DHA are sufficient to produce some virilism in 
the female but in the absence of adequate T there is 
incomplete development of the male. Patients may have 
salt-wasting in severe cases of this disorder. 
DEFICIENCY OF 170HASE 
In these patients progesterone cannot be converted to 
170HP so that synthesis of glucocorticoids and sex 
steroids is inhibited. Males are incompletely masculinised 
and females often present at adolescence with primary 
amenorrhoea. Mineralocorticoid synthesis is not affected 
and' patients with this disorder have elevated 
deoxycorticosterone levels, hypokalaemia, and hypertension 
similar to that observed in patients with 110Hase 
deficiency. 
1.5.3 DEFICIENCY OF 110HASE 
This is the second most common form of CAH. The 
condition was first described by Shepard and Clausen 
(1951) who noted hyperplasia of the zona glomerulosa in an 
infant with marked and persistent hypertension. The 
patient was treated with cortisone acetate when the blood 
pressure fell. Perea et al (1944) had noted that 
7 
deoxycorticosterone administered to a man caused 
hypertension and Shepherd and Clausen speculated that 
their infant might be producing increased levels of this 
hormone. They also noted the advanced bone age of the 
child and advanced epiphyseal maturation. 
Eberlein and Bongiovanni (1955 and 1956), by careful 
study of steroid levels in an 8 year old girl showed that 
this form of CAR was associated with a deficiency of 
11-betahydroxylase. As 11-deoxycortisol is not converted 
into cortisol, accumulated precursors are converted to 
androgens giving rise to the advanced bone maturation. 
As the foetus is subjected to high levels of 
androgens in utero the external genitalia of the female 
are masculinised but the internal genitalia are normal 
(New and Levine (1984)). This virilisation is the most 
prominent feature at birth but hypertension is not always 
noted in the neonate or young child (Grundy et al (1960)). 
There appears to be no correlation between severity of the 
hypertension and the degree of virilisation but about two 
thirds of untreated patients with classic 110Hase 
deficiency become hypertensive, often after several years 
of life (White et al (1987b)). It is at this stage that 
the physician may suspect CAR particularly if there is 
advanced bone maturation. 
The biochemical markers of this form of CAR are 
markedly elevated levels of 11-deoxycortisol and 
ll-deoxycorticosterone. Tetrahydro-metabolites of these 
compounds are present in urine at several times the normal 
trace concentrations and are diagnostic for the disorder. 
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Cortisol metabolites are usually excreted in normal 
amounts but plasma levels of A4 and T are elevated. Serum 
potassium levels may be low or normal and plasma renin and 
aldosterone are suppressed. The condition is treated by 
replacement doses of hydrocortisone and, in some cases, 
cyproterone acetate which as an 
suppress bone maturation to allow 
anti-androgen helps 
maximum height to 
attained before fusion of the epiphyses. 
1.6.1 DEFICIENCY OF 210HASE 
to 
be 
This is the most common form of CAH and as it is the 
variant of primary interest in this thesis the clinical 
and biochemical presentation at diagnosis, and as a 
consequence of treatment, will be considered in detail. 
210Hase is the enzyme responsible for conversion of 
170HP to 11-deoxycortisol (see Figure 1), the immediate 
precursor to cortisol. A deficiency of the enzyme results 
in low production of cortisol and by negative feedback on 
the hypothalamuB increased secretion of ACTH from the 
pituitary. This in turn leads to increased production of 
precursors proximal to 21-hydroxylation giving rise to 
high levels of 170HP which is metabolised via DHA to the 
androgens. 
1.6.2 CLINICAL PRESENTATION 
The increased synthesis of androgens in utero leads 
to masculinisation of the external genitalia and 
cliteromegaly. The internal female organs, however, 
develop normally. The cliteromegaly, with its likeness to 
a penis, has lead to misclassification of the gender of 
the foetus at birth, as was the case in the original 
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description of this disorder by de Crecchio, which may 
lead to severe psychological effects on the child and its 
parents. 
In untreated patients the increased androgens lead 
to rapid growth and maturity of the bones. This is 
referred to as an increase in "bone age", which is 
assessed clinically by X-ray of bones in the wrist. A 
score of relative maturity is assigned to each of 20 bones 
and the total score compared on a nomogram of score versus 
chronological age. From this an estimate of the years of 
bone age advance may be made. Increased bone age results 
in early fusion of the epiphyses and a short adult. The 
increase in blood androgen concentration also gives rise 
to early development of pubic hair, acne and excessive 
growth of the penis and clitoris. 
In untreated adult females increased levels of 
progesterone inhibit the release of oestradiol prior to 
the LH surge of ovulation resulting in absent or irregular 
menses. In the case of an affected adult male the high 
levels of circulating androgens suppress gonadotrophin 
release such that the concentration of T in the testes may 
be low leading to poor spermatogenesis. 
1.6.3 BIOCHEMISTRY OF 210HASE DEFICIENCY 
in 60 
With 
80% of 
diminished 
Aldosterone biosynthesis is affected 
cases of classic 210Hase deficiency. 
levels of this mineralocorticoid, sodium 
the renal tubule is reduced leading to 
electrolyte imbalance of low plasma 
reabsorption in 
potassium. 
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a characteristic 
sodium with high 
There has been controversy over the biochemical basis 
for the differences between the simple virilising and the 
salt wasting forms of the disorder. Bongiovanni and 
Eberlein (1958) found that in both forms there was 
defective 21-hydroxylation of 17-hydroxysteroids resulting 
in an elevation of 170HP and diminished production of 
cortisol and suggested that the 210Hase defect was more 
severe in salt-losers than in non salt-losers. However 
West et aI, (1979), based on measurement of cortisol, 
aldosterone and their precursors suggested that there were 
2 different 210Hase systems, one for conversion of .170HP 
to cortisol and the other for the metabolism of 
progesterone to aldosterone. In non salt-losers the latter 
system would be intact. They further suggested that there 
may be more than one form of the enzyme in the zona 
glomerulosa so leading to the multiple enzyme theory. 
Kuhnle et al. (1981) further complicated the 
discussion by suggesting a "two gland model" in which 
there is a defect in 21-hydroxylation in the zona 
fasciculata and in salt wasting an additional defect in 
21-hydroxylation in the glomerulosa. In the simple 
virilising form the glomerulosa is spared this defect. 
1.6.4 DETECTION OF 210HASE DEFICIENCY 
Early methods for the detection of CAH depended on 
measuring urine steroids in 24 hour collections. Some 
centres are able to carry out full steroid profiles on 
urine and this can be useful in difficult cases but in 
most laboratories the measurement of 170HP in blood is the 
method of choice for diagnosing 210Hase deficiency. 
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This form of CAB is the commonest in occurrence with 
an incidence of 1 in 5000 to 1 in 67000 in most white 
populations (Qazi and Thompson (1972)) and of 1 in 490 in 
Yupik Eskimos in Alaska (Birschfield and Fleshman (1969)). 
Of the inborn errors of metabolism CAB is relatively 
common compared to phenylketonuria (PKU) for which there 
is a mandatory screening programme in the UK. A review of 
the practice of neonatal screening was presented by the 
Public Bealth Committee of the Council of Europe in 1981 
(Bickel et al. ). They noted that screening for CAB was not 
yet feasible as a cheap, simple method for measuring 170BP 
in blood, suitable for dealing with large numbers, was not 
available. Neonatal mass screening was thought to be 
appropriate in diseases which are treatable, are not 
easily recognised by clinical means during the neonatal 
period and need therapy to prevent irreversible 
disabilities. The Committee agreed that CAB fell within 
these terms of reference and recommended that it be 
included in a list of recommended tests for the future. 
Screening programs are currently being carried out in 
Alaska, Washington, Illinois and Texas. 
1.6.4.1 SCREENING USING BLOOD SPOT 170HP 
Various groups have looked 
screening. Pang et al. (1977) were 
at methods 
the first 
for mass 
group to 
publish a paper for measuring 170HP in blood spotted onto 
filter paper cards, as used for Guthrie tests on neonates 
for the detection of PKU. They eluted the steroid from a 
3 mm diameter punched out disc using assay 
extracted the 170HP with diethyl ether prior 
by radioimmunoassay (RIA). They calculated the 
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buffer and 
to analysis 
amount of. 
serum ccntained in each disc from the haematocrit and 
found this to range from 2.2 to 4.4 pLo The steroid was 
stable for at least 21 days when stored at room 
temperature. They found the concentration of 170HP in an 
aliquot of whole blood to be the same as in the filter 
paper disc. It was not measurable in washed red blood 
cells indicating that the hormone is only present in the 
plasma phase. They found levels of 170HP to be higher in 
sick infants however these were considerably less than 
those found in infants with 210Hase deficiency. Davis 
(1977) found that the size of the blood spot on the 
filter paper was an important source of error in 
thyroxine (T4) screening in neonates. According to 
whether the disc was punched from the centre of the spot 
or from an edge could make a difference of 50% in the 
level of T4 measured. Davis found that the quantity of T4 
per disc was influenced by a chromatographic effect which 
caused an accumulation of T4 on the periphery of the spot 
and an apparent "build-up" in blood which increased with 
the total volume of sample added to the same spot on the 
paper. This might be due to over-saturation of the 
absorbent capacity of the paper. Davis suggested 
standardising, as far as pOSSible, the size of the blood 
spot and ensuring that the disc is punched from the 
centre of the spot each time. 
Solyom et al. (1981) noted that in Hungary with a 
population of 10 million they would expect 100 - 200 cases 
of CAH per year. They performed a prospective study to 
investigate the value of blood spot 170HP as a screening 
technique. In healthy infants aged 6 to 90 days they found 
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170HP levels up to 45 nmol/L. Healthy newborns at ages 
to 5 days had concentrations up to twice this level and in 
stressed patients up to 3 days of life values up to 230 
nmol/L were obtained. However these levels all fell below 
45 nmol/L on repeated sampling. 10 out of 35 patients 
suspected of having CAH on clinical grounds all had values 
ranging from 186 to 3600 nmol/L. No overlap of values from 
affected and normal infants after 6 days of life was 
found. Pang et al. (1982) used blood spot 170HP in a pilot 
newborn screening programme in Alaska. They monitored 
19677 consecutive births and found 16 to have values of 
170HP greater than 56 pg/disc of which 4 (3 Yupik Eskimos 
and caucasian) were proven to be salt-losers. They found 
the incidence of salt-losing CAH to be 1 in 282 amongst 
the Eskimos and 1 in 13700 caucasians. The onset of 
hyperkalaemia occurred in all 4 newborns between the 6th 
and 14th days of life. All the female infants with high 
170HP had ambiguous genitalia. 6 newborns with 170HP 
levels above 56 pg/disc were all premature and levels 
fell below 40 pg/disc on repeat specimens collected 10 to 
40 days later. 
1.6.4.2 170HP IN PREMATURE AND STRESSED INFANTS 
Cacciari et al. (1983) in a large study of 42,930 
infants born in one region of Italy collected blood spots 
between days 2 to 5 of life, almost half being on day 5. 
They found infants with 170HP concentrations of up to 20 
pg/disc had no clinical or confirmatory biochemical 
evidence of CAH. Where values were higher than this they 
were confirmed by a second assay. 88 of the infants tested 
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showed an initial value of greater than 20 pg/disc. On 
retesting 5 of these were found to have proven CAH giving 
an overall incidence of 1 in 8586 neonates. 70% of those 
requiring a retest were from premature infants born before 
37 week gestation but none of these had proven CAB. 
Bughes (1979) compared 170HP concentrations in mixed 
cord blood and in a group of normal newborn infants with 
CAR. They found raised cord plasma 170HP concentrations 
reflecting placental production of the steroid. 170HP in 
specimens collected between 3 and 36 hours showed a steady 
fall with a pronounced difference between levels in 
normal infants compared to those from infants with CAH 
where levels remained high. They also found marginally 
raised levels in infants who were stressed. The authors 
recommended that samples for 170HP be taken after 24 hours 
of life. 
Murphy et al. (1983) in a study of 47 ill newborn 
infants and 53 healthy term control infants found plasma 
levels of 170HP in the ill term babies to be significantly 
higher than the well term sub~ects (means 4.4 and 10.6 
nmol/L respectively). In well pre-term babies the mean 
concentration was 13.6 nmol/L but in ill pre-term infants 
the mean was 24.4 nmol/L with the highest level being 110 
nmol/L - around the minimal level expected in neonates 
with CAH. All of their study subjects were shown 
no endocrine abnormalities. This shows the need 
to have 
to be 
cautious in interpreting raised 170HP levels in pre-term 
babies. A repeat specimen should be assayed for 170HP 
after treatment of the primary illness. 
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1.6.5 NON CLASSICAL 210HASE DEFICIENCY 
This form of CAH, otherwise referred to as "late 
onset", is a less severe defect. Genetic females with this 
form do not have prenatal virilisation but both sexes 
experience a varying degree of androgen excess 
post-natally. The clinical presentation is characterised 
by early development of pubic hair, hirsuitism, acne and 
menstrual disturbances which begin in late childhood or 
early adulthood (New and Levine (1984)). The incidence of 
this form may be as high as 3 in 1000 of the general white 
population and even up to 3 in 100 in Jews of European 
origin making CAH an important cause of infertility in 
this ethnic group (Birnbaum and Roso (1984)). 
New and Levine (1984) have published a nomogram 
comparing plasma 170HP levels before and one hour after 
stimulation of the adrenal with synthetic 
with classic 210Hase deficiency, those 
ACTH. Patients 
with the 
non-classical form, heterozygotes and normal persons have 
levels of 170HP which plot on distinct parts of the curve. 
1 .6.6 GENETICS OF 210HASE DEFICIENCY 
This form of CAH is inherited as an autosomal 
recessive trait and is closely linked to the gene for 
human leukocyte antigens (HLA) which are cell surface 
antigens important in transplantation. These are located 
on the short arm of chromosome 6. Siblings who both have 
identical 210Hase deficiency usually have identical HLA 
types and HLA typing can be used to determine the carrier 
status of any member of the family (Levine et al. (1978)). 
Genetic counselling is available for parents with an 
affected child who may be hoping for further children. 
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1.6.7 PRENATAL DIAGNOSIS 
Until recently 2 methods of prenatal diagnosis were 
available to parents who already have one child with CAH. 
The first involves measurement of 170HP in amniotic fluid 
and the second HLA typing of amniotic cells (White et al. 
(1987b)). For both of these amniocentesis is required at 
16 weeks of gestation and by this age an affected female 
foetus will already have undergone masculinisation. 
Chorionic villus sampling can provide material for 
analysis around 10 weeks of gestation and specific DNA 
probes can be used to identify the condition. In the 
future it may be possible to administer dexamethasone, a 
synthetic corticosteroid 20 to 80 times as potent as 
cortisol (Myles and Daly (1974)), to the mother around the 
10th week of gestation to suppress the androgen levels and 
avoid virilisation in the female foetus. However it is 
unlikely that this technique will be available for 
general screening. 
1.6.8 REPLACEMENT THERAPY 
The treatment of 210Hase deficiency has recently been 
reviewed by Cutler and Laue (1990). The infants with the 
salt losing form require mineralocorticoid replacement 
which is normally given as fludrocortisone. In addition 
both forms of the disorder require hydrocortisone 
replacement. In patients with the milder defect a dosage 
of 12 to 15 mg per square metre of body surface area per 
day is usually taken in divided doses. In those with the 
more severe defect the daily dosage may need to be 
increased to 25 mg. 
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The aim of the treatment is to promote the maximum 
gain in height before fusion of the epiphyses and the 
effectiveness can be monitored by measurement of the 
patient's growth velocity and bone age in addition to the 
biochemical parameters to be discussed later. 
When the child reaches puberty prednisolone can be 
used instead of hydrocortisone and may be taken as a 
single dose. 
1.7 MEASUREMENT OF STEROID HORMONES 
The naturally occurring steroids are present in 
biological fluids in very small concentrations ranging 
from micromole levels of some adrenal steroids in urine to 
picomole and femtomole concentrations of other steroids in 
saliva. Because of this and also the similarity in 
structure it has been usual to extract steroids from 
biological fluids using organic solvents and then to 
perform further purification by chromatography. 
SPECTROPHOTOMETRIC METHODS 
The reactivity of chemical groups on the steroid 
molecule has been used to develop assays for steroids in 
urine. For example steroidal ketones will condense with 
meta-dinitrobenzene to give a complex which is oxidised to 
give an intensely coloured chromophore (Appleby (1955)). 
This reaction has been used extensively in the measurement 
of 17-oxosteroids (metabolites of the androgens) and 
17-oxogenic steroids (metabolites of 
17-hydroxycorticosteroids) in urine. Early methods for the 
biochemical diagnosis of CAH involved measurement of 
P-TRIOL in 24 hour urine collections. This was achieved 
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using sulphuric acid c.hromogens and later gas liquid 
chromatography (GLC). Before the introduction of specific 
methods for 170HP in serum or P-TRIOL in urine ·the 
measurement of these steroid metabolite groups was used 
for monitoring the treatment of children with CAR. The 
problems were the relative insensitivity of the methods 
and the requirement for a 24 hour urine collection. 
PAPER CHROMATOGRAPHY 
This medium has been used extensively for 
complex mixtures of sterolds (Bush (1952». The 
separating 
steroids 
are chromatographed into individual bands whi ch can then 
be identified by colour reactions with the side groups 
and the appropriate fractions eluted from the paper. 
THIN LAYER CHROMATOGRAPHY 
This was used in early steroid work for group 
location (Shulster et al. (1976». The resolving power for 
steroids was comparable with other chromatographic methods 
and the sample capacity was greater than that of paper. 
GAS-LIQUID CHROMATOGRAPHY 
GLC has been used extensively in urine steroid 
profile studies as well as for quantitation. However the 
sensitivity is such that for measurement of indivldual 
steroids in plasma 2 to 3 
However with the addition 
technique can be useful in 
forms of CAH. 
mls of sample lS required. 
of mass spectrometry the 
differentiating the various 
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1.7.5 
CAH 
CHROMATOGRAPHIC PROCEDURES IN THE DIAGNOSIS OF 
Edwards et al. (1964) described a method which 
determined all the 17-hydroxylated corticosteroids and 
their metabolites and gave a ratio 
17-hydroxylated corticosteroids which had 
of 
not 
those 
been 
ll-hydroxylated (ie cortisol precursors) to those which 
had (ie cortisol and cortisone). This ratio was referred 
to as the 11-oxygenation index (1101). The method involved 
borohydride reduction of keto-groups followed by oxidation 
with periodate to cleave the 17-21 carbon side chain and 
form 17-oxosteroids. This was followed by extraction with 
dichloromethane and paper chromatography to separate the 
11-oxy and ll-deoxy zones. These areas were then located 
by immersion of the paper in alkaline meta-dinitrobenzene 
to form the purple colour of the Zimmerman reaction 
(Appleby et al. (1955)). The areas were then cut out, 
eluted with dimethylsulphoxide and the absorbance of each 
solution measured. The ratio could then be calculated. 
The index had the advantage of requiring only a random 
urine but Clayton et aL (1971) in a study of 97 patients 
found a high ratio in 23 who were later shown not to have 
CAR. Of these 23, 5 had increased levels of the Index 
which fell by the eighth day of life. 2 were found to be 
excreting l-oxygenated steroids and had impaired 
adrenocortical function and 10 boys had diarrhoea. 
1.7.6 SATURATION ANALYSIS TECHNIQUES 
This group of techniques developed from the work of 
Yalow and Berson (1959) on the RIA of plasma insulin 
us ing an anti body to insulin and the lvork of Ekins ( 1960) 
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on the assay of T4 using thyroxine binding globulin. In 
this type of assay there is competition between a fixed 
amount of the hormone of interest, labelled with 
radioactivity or enzymes, and the endogenous hormone in 
the specimen for binding sites on a specific protein. Thus 
the less hormone there is in the sample undergoing assay 
the more labelled hormone is bound to the antibodies and 
vice-versa. 
The primary combination of antigen (Ag) and antibody 
(Ab) can be depicted by the equation: 
Ab Ag K. Ab - Ag + • 
• 
11"2. 
K ... = [Ab - Agl 
[Ab] [Ag] 
where k, and k~ are the rate constants for the forward and 
reverse reactions respectively and K ... is the equilibrium 
constant for the overall reaction. 
After· incubation the hormone (both labelled and 
endogenous) bound to the protein can be separated from 
unbound hormone using a variety of separation methods. The 
amount of labelled hormone which is bound can then be 
found by counting the radioactivity in an appropriate 
counter or, in the case of an enzyme label, by addition of 
substrate and chromogen and measurement of the colour 
product. 
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1.7.6.1 COMPETITIVE PROTEIN BINDING (CPB) 
Early methods for steroids used endogenous binding 
proteins. Murphy et al. (1963) described an assay for 
cortisol using corticosteroid binding globulin (CBG) and 
carbon-14 labelled cortisol. Dialysis of 1 mL of plasma 
was required before use in the assay. Subsequently it was 
shown that CBG could be used to measure a number of other 
steroids of similar structure. Yoshimi and Lipsett (1968) 
published a method for progesterone in which 5 mL of 
plasma was extracted with diethyl ether and the 
progesterone isolated by TLC and purified by column 
chromatography prior to assay using tritiated progesterone 
as label and CBG as binding protein. Strott et al (1968) 
described a similar assay which measured 170HP. 3 mL of 
plasma was extracted with diethyl ether, the extract 
subjected to TLC and appropriate areas eluted into 
methanol:ether. After drying down the solvent the residue 
was acetylated prior to further chromatography, elution, 
drying down and assay with CBG as binding protein. 
1.7.6.2 RADIOIMMUNOASSAY (RIA) 
The more sensitive RIA's superseded the CPB assay. As 
steroids are not antigenic it is necessary to first couple 
the steroid covalently to a large protein such as albumin. 
This complex is injected into animals over a period of 
several months producing antibodies against the antigen 
which have a high binding affinity for the original 
steroid used. The specificities of the antibodies formed 
depend very much on how and where the albumin is coupled 
to the steroid molecule (EI-Gamal et al. (1987)). 
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As steroid molecules all have a similar structure a 
major problem is that the antibodies cross-react with 
other steroids having the closest structures to the one 
being measured. For this reason published methods have 
usually involved extraction of the sample with organic 
solvents followed, in some cases, by chromatography. 
These sample preparation procedures are time consuming and 
require some experience to obtain reproducible results. 
In assays where the steroid of interest is present 
in relatively high concentrations, such as cortisol which 
has a range of 150 to 700 nmol/L in plasma, it has been 
possible to carry out assays on relatively crude extracts 
without chromatography (Ruder et al. (1972)) and more 
latterly directly on the plasma (Seth and Brown (1978)). 
In the earlier methods of ~lurphy mentioned above 
carbon-14 was used as the label. Although it has a long 
half-life of 5450 years it is usually of low specific 
activity requiring long counting times in a liquid 
scintillation counter (LSC). Other RIA's and CPB assays 
have used tritiated steroids, Again these labels usually 
have to be purchased from commercial sources. Although the 
specific activity is higher and the cost lower than 
carbon-14 there is still the problem of long counting 
times. 
Since the late 1970's medical diagnostic companies 
have been marketing reagent kits for measuring a number of 
steroids by RIA. These have generally been robust, 
optimised kits with, latterly,'~I as label. This isotope 
can be measured with efficiencies of around 80% in a gamma 
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counter and with the use of multi-head counters a batch of 
100 tubes may be counted in 10 minutes. A disadvantage is 
I1.S-I that is a large atom which cannot be incorporated 
into the steroid molecule without considerable distortion 
of the stereochemistry. It is therefore necessary to link 
a protein, such as bovine serum albumin (BSA), to the 
steroid and then conjugate the 175 I to this protein. 
Although the specific activity attainable is greater than 
that of tritiated steroids, as the half-life is only 60 
days the use of this isotope can be expensive unless the 
throughput of samples is high. Commercial kits are 
now available for most of the common steroids. 
NON-ISOTOPIC IMMUNOASSAYS 
In the use of RIA's it has been generally accepted 
that the low level of radiation involved in these assays 
presents little danger to the analyst. However the effect 
of long term exposure to low levels is not known and those 
workers involved in preparing the iodinated tracers may 
run a real risk to their health. Whilst established 
endocrine laboratories have invested heavily in automated 
counting equipment for radioisotopes newer laboratories 
are able to take advantage of the many non-isotopic labels 
which can be prepared by themselves or are available 
commercially. 
Blake and Gould (1984) discussed a number of 
advantages of the use of enzyme labels including their 
stability, often for more than a year when frozen. Also 
the enzyme activity can be measured with basic laboratory 
equipment and also have the potential for visual 
assessment for qualitative tests. However they also 
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pointed out some disadvantages whereby, unlike 
radiolabels, many non-isotopic labels respond to their 
chemical or physical environment being affected by, for 
example, pH and ionic strength of the assay buffer and 
temperature of the reaction. Inhibitors, quenchers cr 
potentiators may also present problems with the assay. 
Some steroid assays have been described 
fluorescent labels have been used. Homogeneous 
which do not require a separation step to 
antibody bound label from the unbound label, are 
where 
assays, 
separate 
possible 
utilising fluorescence polarisation, quenching or 
enhancement. Generally homogeneous fluorescence assays are 
less sensitive than RIA because of background fluorescence 
from many proteins and other constituents in biological 
fluids. 
An alternative form of homogeneous 
achieved with the use of co-factor label. 
assay may 
Carrico et 
be 
al. 
(1976) described the use of nicotinamide 
6-(2-aminoethylamino) purine dinucleotide (AENAD), a 
derivative of NAD, to provide co-factor con~ugates which 
were active with several dehydrogenases. 
1.8 ENZYME IMMUNOASSAY (EIA) 
The enzymes which have been most commonly used for 
heterogeneous EIA's are horseradish peroxidase (HRP), 
alkaline phosphatase and beta-galactosidase. Each of these 
may be. detected at femtomole levels by 
spectrophophometry. 
Wisdom (1976) suggested 
labels in EIA should be cheap 
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that 
and 
enzymes 
available 
suitable as 
at a high 
------------------------
purity and high specific activity and be stable under the 
assay and storage conditions. The enzyme itself and its 
substrates and inhibitors should, as far as possible, be 
absent from the biological fluids likely to be assayed. 
The enzymes also need to retain their activity through the 
conjugation procedures needed to link them to the hapten 
of interest. 
The earliest report of an EIA for a steroid is that 
of Van 'ITeeman and Schuurs (1972). They us ea HRP as the 
label for preparing conjugates with oestradiol and 
oestriol. However this assay was not optimised and did not 
achieve the sensitivity of RIA. Dray et al. (1975) claimed 
to have developed the first sensitive EIA ef a hapten with 
the use of beta-galactosidase as the label in an assay for 
progesterone, after petroleum ether extraction of rat 
serum. They claimed a sensitivity of 12 pg/tube and good 
correlation with RIA using the same antibody. There 
followed several further reports of EIA's for steroids 
using various enzyme labels. Numazawa et al. (1977) 
described an EIA for oestradiol using HRP as label and a 
solid phase antibody. Plasma was extracted with diethyl 
ether and chromatographed on Sephadex LH-20. The 
oestradiol fraction was submitted to the EIA and the 
activity of the HRP measured by addition of homovanillic 
acid and hydrogen peroxide. The fluorescence intensity was 
then measured. They were able to detect 50 pg/0.2 mL of 
sample. 
Oestradiol was also measured by Fxley and Pbuknesha 
(1978) using beta-galactosidase as label after extensive 
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purification to remove uncon~ugated enzyme (Exley and 
Abuknesha (1977)). Various doses of oestradiol standard 
were analysed by EIA and RIA and similar sensitivities 
achieved. 
Rajkowski et al. (1977a) used HRP con2ugated to 
testosterone and antibody linked to microcrystalline 
cellulose. They were able to measure 50 pg to 1.5 ng of 
testosterone but did not assay serum. 
The EIA's so far mentioned have either been carried 
out on solutions of steroids in assay buffer or on 
extracts of serum. Ogihara et al.(1977) described an assay 
for cortisol involving a HRP label linked to the 
21-hemisuccinate which could detect 1 pg/dL (30 nmol/L) 
directly on 10 pL of plasma. 
1 .8.1 DISPLACEMENT OF HORMONE FROM BINDING PROTEIN 
The direct measurement of steroids in plasma requires 
a procedure to displace the steroid from its binding 
protein. This has been achieved by a number of methods for 
RIA's. Foster and Dunn (1974) denatured the CBG by 
heating the plasma at 60· C. Kumar et al, ( 1 976 ) used an 
enzyme denaturant and Seth and Brown (1978) a citric 
acid-phosphate buffer at pH 4 to release cortisol from 
the binding protein. The addition cf anilinonaphthalene 
sulphonic acid (ANS) as blocking agent has been used 
extensively for displacement of thyroid hormones from 
thyroid binding globulin (TBG) (Fang and Refetoff (1974) 
and Radcliffe (1974)). Merthiolate was used by Jowett and 
Slater (1977) in an assay for aldosterone. Kane (1979) 
compared the use of these two blocking agents with sodium 
salicylate in an assay for cortisol. 
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1.8.2 USE OF ALKALINE PHOSPHATASE AS ENZYME LABEL 
In their EIA Ogihara et al. (1977) mixed plasma with 
glutamate buffer at pH 3.3 and heated the mixture in a 
boiling water bath for 15 minutes. This denatured the CBG 
and also the endogenous alkaline phosphatase in the 
sample. They then used cortisol labelled with alkaline 
phosphatase in a double antibody method. The EIA had a 
similar sensitivity and specificity to RIA and was 
adequate for the measurement of cortisol in clinical 
specimens. 
Kobayashi and Ogihara et a1. (1978) developed a 
similar assay for cortisol using alkaline 
the label linked to cortisol 21-amine 
phosphatase as 
and cortisol 
21-hemisuccinate-BSA conjugate as the immunogen. This was 
following on from the suggestions of Van Weeman and 
Schuurs (1975) and ITumazawa et a1. (1977) that a 
heterologous combination of conjugates for the generation 
of the antibody and the preparation cf the enzyme labelled 
hormone led to greater sensitivity in the EIA. However 
Kobayashi et al found this method to have a similar 
sensitivity to their earlier HRP EIA which used the same 
hemisuccinate conjugate as immunogen and enzyme link and 
suggested that the assay sensitivity depended on the 
nature of the antibody used rather than the heterologous 
nature of the components employed. 
1.8.3 USE OF BETA-GALACTOSIDASE 
Monji et aL (1980) described a method for measuring 
plasma cortisol using beta-galactosidase as label. As with 
the Ogihara assay the cortisol was released from the CBG 
by heating in a boiling water bath. The enzyme activity 
wasmeasurec as for Dray et al (1975) using 
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o-nitrophenyl-beta-D-galactopyrcnoside as substrate and 
the o-nitrophenol produced measured at 420 nm yielding 
comparable results with RIA. 
1.8.4 HRP AS ENZDIE LAl3EL 
The other enzyme label most commonly used in steroid 
assays is HRP. Joyce et aI, (1977) used this label in an 
ETA for progesterone. The HRP was coupled to 
11-alphahydroxyprogesterone 11-hemisuccinate by a mjxed 
anhydride procedure. The progesterone was first extracted 
from the plasma with petroleum ether. The antibody used 
was linked to Sepharose and on centrifugation formed a 
pellet which could be subsequently washed. The activity of 
the bound HRP was measured using o-phenylenediamjne 
(OPD) as chromogen and hydrogen peroxide as substrate. 
These workers followed up this method with one for 
measuring testosterone in plasma and saliva (Turkes et al. 
(1979». They first extracted the steroid with purified 
diethyl ether. As with the progesterone assay they used a 
solid phase antibody and measured the HRP using OPD. Wjth 
this assay they achieved a sensitivity of 4pg/assay tube 
and results which correlated well with a RTA and also gas 
chromatography/mass spectrometry. 
More recent ETA's for steroids have continued to use 
HRP as label. Preti et al. (1984) us ed it in an ETA for 
measuring oestriol in saliva and plasma in pregnancy. The 
antibody was linked to polystyrene beads. They compared 
ETA measurements of oestriol jn saliva both wjth 
extraction with ciethyl ether and directly on saljva and 
found good agreement. 
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Dhar et aI, (1986) developed an assay for serum 
cortisol utilising a transferable needle lid (TNL) as 
solid phase. The TNL is available commercially and was 
originally designed for screening antibodies in mono clonal 
hybridoma cultures. The immunoassay was carried out in a 
microtitre plate and the TNL, coated with second antibody, 
was dipped into the wells to effect the separation. After 
thorough washing bound enzyme activity was measured by 
transferring the lid to a further microtitre plate with 
the wells containing substrate. This assay used 
tetramethylbenzidine (TMB) as chromogen. Their sample size 
was only 2 pL and they found incubation at 37°C sufficient 
to eliminate interference from CEG. 
A further report of a direct cortisol method is that 
of Dona (1987) which is marketed by ~iles. This is a 
coated tube method, again using HRP with 0.3 mg of ANS and 
2 mg of Eodium salicylate/assay tube to displace the 
cortisol from the CBG and OPD as the chromogen. Comparable 
results were obtained with an RIA method. 
1 .8.5 CHOICE OF ENZYME LABEL 
Many ef the early methods described involved the use 
of beta-galactosidase which has the advantage of being 
absent from human plasma. It can be measured with 
substrates yielding either a colour or by fluorescence. 
Alkaline phosphatase has been used in relatively few 
steroid methods but is inhibited by few blocking agents 
and can be measured by a simple endpoint method using 
p-nitrophenyl phosphate as substrate. However it is 
expensive and is present in varying concentrations in the 
blood of children particularly during puberty. 
The most widely used enzyme, in recent years, for 
published steroid assays has been HRP which is cheap and 
easy to purify (Tijssen (1985)). Its activity is most 
commonly measured using chromogens which produce dark 
colours, facilitating visual assessment in qualitative 
assays. There is also the potential of using other methods 
of measuring the activity such as chemiluminescence and 
fluores cence. 
1.8.6 CHOICE OF CHROMOGEN FOR COLOUR DEVELOPMENT 
Rajkowski et al. (1977b) 
(5AS) to investigate the 
conjugation of testosterone 
colour had an absorbance 
used 5-aminosalicylic acid 
investigated the 
conditions for optimum 
with 
at 470 
HRP. The resulting 
nm. They also 
stabili ty of enzyme-labelled 
testosterone at 5"C for 3 to 37 days with frequent 
assaying of the enzyme activity. They found a 
concentrated solution to be stable for over a month with 
working strength solutions stable for at least 6 days. 
However they recommended lyophilising the labelled 
testosterone for long term storage. 
Another popular chromogen is 2,2'-azino-di(3-ethyl-
benzthiazolinesulphonio acid) (ABTS). This was used by 
Munro and Stabenfeldt (1984) in a microtitre plate assay 
for progesterone. A mixed anhydride procedure was used for 
preparation of the enzyme-progesterone label and it was 
the protocol outlined in this paper which was used as the 
labelling procedure for 170HP in the present project. 
A disadvantage of OP] and ABTS is that they have 
been found to be carcinogenic. 5AS is not carcinogenic but 
it, and its products, are only sparingly soluble. 
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Bos et al. (1981) investigated the use of 
3,3',5,5'-tetramethylbenzidine (TMB) as the chromogen in 
an EIA for testosterone. TMB had been shown to be 
non-carcinogenic and non-mutagenic. They used TMB at a 
concentration of 10 g/L in various organic solvents and 
found dimethylsulphoxjde (DMSO) to be most appropriate. 
v/hen used in acetate buffer at pH 6 with 1.3 mmol hydrogen 
peroxide a blue colour developed with 3 absorbance peaks 
at 370, 450 and 655 nm. The small peak at 450 nm was 
absent at low enzyme concentrations but there was a linear 
relationship between the absorbance at 655 nm and the 
peroxidase concentration. 
On addition of 2M sulphuric acid the blue colour 
changed to yellow with only one sharp peak at 450 nm 
giving a doubling of overall colour intensity. A similar 
result was obtained with the addition of 4M hydrochloric 
acid however the colour was stable for about 90 minutes 
wi th the sulphuric aci d whereas there \~as rapi d 
non-specific oxidation with the hydrochloric acid. The 
optimum pH for the incubation was found to be 5.0 to 6.0 
in acetate buffer. 
The authors found the peroxidase reaction with TMB 
to be complete after 60 minutes incubation at room 
temperature. In contrast to OPD it is not susceptible to 
light and needs no special precautions during incubation. 
1.8.7 PROBLEMS IN THE USE OF HRP AND STABILISATION 
OF COLOUR WITH NON-IONIC DETERGENTS 
There are several problems with the use of peroxjdase 
since this enzyme is much more sensitive to contaminants 
than is alkaline phosphatase. Peroxidase is also sensitive 
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to the presence of bacteria or bacteriostatic agents, eg 
sodium azide, and is inactivated by oxygen, hypochlorous 
acid and aromatic chlorocarbons which are often found in 
laboratory water (Tijssen (1985)). 
A further complication in the use of peroxidase is 
the observation that the enzyme is inactivated in the 
course of the reaction with chromogen and substrate. This 
inactivation is thought to be caused by complex formation 
with the hydrogen peroxide. Porstmann et al (1981) 
established that the presence of excess hydrogen peroxide 
alone only caused slight inactivation and the presence of 
only chromogen failed to procuce any inactivation. They 
studied the effect of the use of non-ionic detergents on 
the kinetic behaviour of the peroxidase and found this 
gave protection to the enzyme from growing inactivation 
during the reaction. The extent to which the enzyme 
activity was protected depended on the chromogen used. 
They found that the sensitivity of EIAs could be doubled 
by the addition of these non-ionic detergents to the 
substrate mixture such that shorter incubation times were 
needed for colour development. 
The effect of inclusion of non-ionic detergents in 
the substrate solution was studied for the 2 chromogens 
used in this project. 
1.9 SEPARATION OF FREE AND BOUND HORMONE 
After incubating immunoassays it is necessary to 
measure the relative propo~tion of antigen which is bound 
to the antibody. Usually this involves a physical 
separation. 
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The -main requirements of an ideal 
technique have been described by Ratcliffe 
Collins et al, (1975) as: 
separation 
(1974) and 
i) Complete separation of bound and free fractions with 
a wide margin of error in the conditions used. 
ii) No interference with the primary antigen-antibody 
binding reaction. 
iii) Simple, easy and rapid to use. 
iV) Inexpensive and involve the use of reagents and 
equipment v,hich are readily available. 
v) Not affected by the matrix of the body fluid used in 
a direct assay. 
vi) All manipulations to be carried out in a single 
assay tube. 
vii) Suitable for automation. 
viii) Applicable to a wide range of antigens. 
Ratcliffe reviewed the various techniques used for 
separation of free and bound fractions and described 5 
main groups:-
1 .9.1 DIFFERENTIAL MIGRATION OF BOUND AND FREE 
FRACTIONS 
This includes the paper chromatoelectrophoresis 
method used by Yalow and Berson (1960) in their assay of 
insulin. This was, however, expensive and slow. 
1.9.1.1 GEL FILTRATION 
This is an alternative procedure in this group which 
was utilised by Murphy and Pattee (1964) in their CPB 
assay for plasma corticoids. As bound complexes are larger 
in molecular volume than the free antigens they can be 
separated using an appropriate grade of Sephadex. As the 
incubation mixture is applied to a column of gel the 
antibody-bound fraction passes through the column leaving 
the free antigen within the gel particles. This is a 
rather slow procedure when a large number of tubes are 
involved. 
1 .9.2 ADSORPTION METHODS 
These methods, which involve adsorption of the 'free' 
fraction, are widely used in immunoassay procedures. They 
are generally rapid, simple and capable of dealing with a 
large number of samples in a batch procedure. 
1.9.2.1 CHARCOAL 
Charcoal has been used extensively in steroid RIA's, 
particularly those involving the use of a tritium label. 
Whilst it can have wide application strict timing of the 
separation step is necessary. 
1.9.2.2 SILICATES 
These have a high silica content and large surface 
area and are added directly to incubation tubes in powder 
or tablet form. Adsorption is rapid and separation is 
simple ~lith good packing on centrifugation. As with 
charcoal, adsorption to silicates depends on the protein 
concentration in the reaction so optimum 
to be determined for each assay using 
methods. 
1.9.3 FRACTIONAL PRECIPITATION 
conditions 
either of 
need 
these 
This method, which utilises neutral salts or organic 
solvents, depends on precipitation of immunoglobulins at a 
critical concentration of the precipitant. This leaves the 
'free' fraction in solution. Optimal conditions are 
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dependent on pH, buffer, protein and salt concentration. 
Precipitation methods are influenced by protein 
concentration and require standards and samples to have a 
similar protein balance. Ammonium sulphate has been 
employed in many assays but ethanol is more versatile. 
Polyethylene glycol is now the most commonly used in this 
type of separation procedure. 
1.9.4 DOUJ3LE ANTIBODY 
This is one of the most widely used separation 
techniques. The first antibody, raised against the hapten, 
is usually produced in a small animal (eg a rabbit). The 
second antibody is then raised in large animals (eg 
donkey, goat or sheep) against purified IgG of the first 
animal. The second antibody needs to be carefully screened 
before use, to ensure that it does not cross-react with 
human IgG and serum components. 
1.9.4.1 POST PRECIPITATION METHODS 
This is the most commonly used version in which the 
second antibody is used to precipitate the soluble 
antigen-antibody complex formed in the first antibody 
reaction. Ratcliffe (1974) listed various factors which 
affect the double antibcdy separations:-
a) conditions of the second antibody incubation and 
centrifugation. 
b) the carrier protein concentration. 
c) characteristics and concentration of the second 
antibody. 
d) "non-specific" effects due to serum, plasma and 
anticoagulants such as EDTA or heparin. 
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Using this method in a direct assay on plasma or 
serum it is often necessary to include antigen-free serum 
in the standard tubes as the protein content may impair or 
enhance binding of the second antibody. The effect is 
particularly marked when the serum/plasma content is 
greater than 10% and is only negligible when it is less 
than 1%. 
1.9.4.2 PRE-PRECIPITATION METHODS 
In this technique first antibody is precipitated by 
incubation with second antibody prior to the main 
immunoassay incubation. Serum proteins or anticoagulants 
do not interfere, however the sensitivity of the assay may 
be less if the affinity of the first antibody is altered 
in its binding to the second antibody. 
1.9.4.3 DOUBLE ANTIBODY SOLID PHASE 
In this technique a second antibody is conjugated to 
an insoluble matrix, commonly Sepharose or cellulose. No 
carrier protein is required, the loss of sensitivity 
encountered in a pre-precipitation method is avoided and 
the method is generally applicable to a wide range of 
assays. 
The relative merits of these 
studied by Becket et aI, (1983) in a 
3 approaches were 
RIA for cortisol. 
They found the pre-precipitated antibody method gave the 
most reproducible results but noted that other workers 
preferred solid phase assays. 
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1.9.5 ·SOLID PHASE ANTIBODY ASSAYS 
There are two principal forms of this technique: 
1.9.5.1 ANTIBODY COATED DISCS, TUBES OR MICROTITRE 
PLATES 
Many commercially produced kits are 
technique. A suitable dilution of first 
now using this 
antibody in an 
appropriate buffer is incubated in polystyrene or 
polypropylene tubes, the wells of microtitre plates or 
with small spheres or discs. This incubation has to be 
carefully controlled to ensure reproducible binding of 
antibody. Kricka et al. (1980) reported that different 
sources of tubes, and even differerit batches from the same 
source, can give widely varying results and it is this, at 
present, which limits their use in "in house" assays. 
The kinetics of the solid phase system 
liquid phase immunoassays in that the binding 
to antibody is virtually irreversible and 
differ from 
of antigen 
hence the 
separation step does not disturb the equilibrium. If the 
variability in production can be overcome then this 
technique may have wide application. 
1.9.5.2 ANTIBODY LINKED TO FINELY DIVIDED SOLID PHASE 
In this case antibody is coupled to cyanogen-bromide 
activated dextran or cellulose particles such as Sephadex 
G25. Particle sizes need to be such that they remain in 
suspension throughout the incubation period, but this can 
be relatively brief, typically 60 90 minutes, and 
separation is by centrifugation. Hindawi et aI, (1980) 
described a direct ErA for cortisol in plasma which 
utilised this technique. 
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The centrifugation stage can be a disadvantage in 
enzyme immunoassay when the solid phase may need to be 
washed. several times with buffer to remove unbound enzyme 
label. In the case of antibody coated tubes or microtitre 
plates washing is easy, quick and can be automated. 
Another form of solid phase which was developed in 
the 1970's and which has recently become popular in 
isotopic immunoassays is magnetisable particles linked to 
antibodies. 
1.10 MAGNETISABLE PARTICLES AS SOLID PHASE FOR 
FIRST AND SECOND ANTIEODY SEPARATION 
Two groups, working independently, simultaneously 
developed the concept of linking antibodies to a magnetic 
support for use in RI As utilising a magnet to separate 
free from bound fractions. 
Hersch and Yaverbaum (1975) in a RIA for digoxin 
used black ferric oxide activated with an amino-silane 
derivative as the solid phase for the 
Microscopic examination of the magnetic 
antibody. 
particles 
indicated that they were irregular in shape with diameters 
ranging from 1.5 to 10 pm. The secimentation rate, 
measured by observing the absorbance at 500 nm, was found 
to have a half-life of about 5 minutes requiring the tubes 
·in the assay to be mixed at 5 minute intervals to keep the 
antibody in suspension. Separation was achieved by placing 
the tubes in a "U" magnet for 45 seconds. 
Nye et al. (1976) coupled antibody to Enzacryl FEO-M, 
a pOlymer-coated iron oxide, which is available 
commercially. These authors developed assays for T4, 
digoxin and human placental lactogen and also an assay for 
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human chorionic gonadotrophin using second antibody linked 
to magnetisable particles. Again these particles were 
dense and required constant mixing during the incubation. 
This was achieved by the use of a pulsed magnetic field 
across the rack from an electromagnet which was switched 
to continuous field for the separation step. They could 
only use the magnet for short periods, because of 
overheating, and this limited the batch size. The use of 
sOlid-phase second antibody had the potential of wide 
applicability. Also this system required about 10 times 
. less antiserum to achieve the same results as a liquid 
separation technique. 
Forrest and Rattle (1983) listed the features of an 
"ideal" magnetisable particle for antibody i=obilisation 
as includ ing: 
1. A simple and convenient method for linking of antibody 
preferably without prior activation. 
2. Remain in stable suspension during incubation. 
3. Have a high magnetic response to ensure rapid 
separation. 
4. Have a large surface area to provide high antibody 
binding capacity but low non-specific binding. 
5. Be suitable for use with normal pipetting systems. 
6. Be stable in aqueous solution. 
7. Be inexpensive and easy to prepare. 
The most used particles are those based on a 
modified cellulose iron oxide composite which was 
originally developed by Robinson et a1. (1973) for enzyme 
immobilisation. These workers found that the enzyme 
activities of alpha-chymotrypsin and beta-galactosidase 
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were not affected by the application or withdrawal of a 
magnetic field. Settling times for particles in the 
magnetic field ranged from 45 seconds for 55 pm size 
particles to less than 10 seconds for 120 um. 
Guesdon and Avrameas (1977) used magnetisable 
particle separation in EIAs for immunoglobulins. They 
prepared batches of polyacrylamide-agarose beads 
containing different amounts of iron oxide ranging from 
2.5% to 20%. By sieving, beads having diameters between 
50 and 160 pm were selected. Non magneti c bead s were 
removed by washing, sedimentation on a magnet and 
decantation. Using glutaraldehyde aldehyde groups were 
introduced on the beads and antigens and antibodies 
coupled through these groups. The authors found that 
beads prepared in the presence of 7 and 10% iron oxide 
possessed good mechanical and magnetic properties and 
were easy to handle. 
Forrest (1977), whilst working for the Technicon 
Corporation, developed a continuous flow system using 
basic autoanalyser technology and antibodies covalently 
linked to magnetisable particles and Il(I as label. The 
incubation time was precisely controlled and separation 
of bound and free achieved by applying an external 
magnetic field across the moving stream. The assays 
available were T4, digoxin, human placental lactogen and 
cortisol. 
Pourfarzanah et al. (1980 ) described a 
fluoroimmunoassay for the measurement of cortisol using ah 
antibody to the steroid coupled to magnetisable 
cellulose/iron oxide particles. They had to keep the 
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magnetic particles in suspension throughout the incubation 
by constantly mixing on a mechanical shaker. On completion 
of the incubation and sedimentation of the solid phase the 
antibody-bound labelled cortisol was eluted into 
methanol:sodium hydroxide and the fluorescence of the 
supernatant measured. 
Magnetisable particle separation has been used for 
the assay of 170HP by 2 groups. Dyas et al. (1984) linked a 
first antibody against 170HP to magnetisable cellulose 
obtained from Serono Diagnostics. The assay involved 
prior solvent extraction of plasma, saliva or amniotic 
fluid and RIA using iodine-125 as label. This enabled 
large batches to be assayed when samples were received 
from paediatric outpatient clinics. 
A more recent paper by EI-Gamal et al. (1988) 
described the use of sheep antiserum covalently coupled to 
magnetisable particles and fluorescein labelled 170HP. 
Their assay measured 170HP directly on 100 pL of serum. 
Using sodium salicylate to block binding of 170HP to 
endogenous binding proteins they developed an assay where 
the results compared well with those obtained from a 
reference method involving extraction, chromatography and 
immunoassay with tritium as label. However the assay tubes 
required constant mixing during the incubation period to 
keep the magnetisable particles in suspension. 
Forrest and Rattle (1983) suggested that the smaller 
the size of the particle, of the order of 1 pm, the longer 
it remains in suspension during the incubation, however on 
applying the magnetic field sedimentation is slow. 
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Particles of around 3 pm have been found to be more 
suitable in immunoassays particularly when used with 
second antibody. Where long incubation times are required 
it is possible to keep these particles in suspension for 
about 1 hour by adding 0.8% w/v hydroxypropyl 
methylcellulose to the assay buffer to increase the 
viscosity. 
Ratcliffe (1974) noted that conventional liquid 
phase double antibody separation should provide the 
reference method against which all other separation 
techniques should be judged. However conventional second 
antibody separation can be expensive when large amounts of 
second antibody need to be used to produce a good pellet 
and the procedure is slow. Second antibody linked to a 
solid phase overcomes this problem since less second 
antibody, by a factor of one hundred or more, is required 
and fast separation in 5 to 10 minutes is possible 
(Forrest and Rattle (1983)). In EIA washing of the bound 
phase is often required before adding substrate to reduce 
the blank absorbance resulting from the presence of free 
enzyme not bound to hapten. This washing step can be 
tedious when repeated centrifugation is required, 
however, with second antibody linked to magnetisable 
particles these washing and sedimentation stages can be 
performed rapidly and easily. 
DAMP has been used as the separation system in this 
current project. 
1.11 COMMERCIAL SYSTEMS AVAILABLE FOR NON-ISOTOPIC 
IMMUNOASSAYS 
A number of non-isotopic immunoassay systems have 
been developed commercially for hormone assays and those 
currently available will now be briefly reviewed. Some of 
these systems can be semi-automated by the use cf sample 
pipetting/diluting stations and automated detection 
systems. 
1.11.1 MICROTITRE PLATES 
Several companies are currently marketing kits using 
mono clonal antibodies linked to the wells of microtitre 
plates. A variety of labels and detection systems are in 
use. Pharmacia market DELFIA (Dissociation-Enhanced 
Lanthanide Fluoroimmunoassay) which uses the fluorescent 
properties of a lanthanide metal chelate as label. On 
completion of the immunoreaction an enhancement solution 
is added in which the europium chelate label 
and forms a new chelate with components 
dissociates 
of the 
enhancement solution inside a protective micelle. This is 
highly fluorescent and is protected from the quenching 
effects of water by the micelle. The fluorescence of the 
europium chelate is then measured. At present kits are 
available for various tumour markers, 
gonadotrophins and blood bank screening 
the only steroid assay available. 
Amersham International market the 
thyroid hormones, 
but cortisol is 
Amerlite 
using peroxidase as the enzyme label 
system, 
and 
chemiluminescence as the detection system •. After the 
immunoreaction and washing of the plate a signal reagent 
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consisting of p-iodophenol and luminol is added. The 
chemiluminescence is generated over a 20 minute period 
and measurement can take place any time after a 2 minute 
delay period to allow for full development of the 
reaction. This same reaction could be used for the 
measurement of peroxidase action in this current project. 
The Amersham range includes thyroid hormones, some 
pituitary hormones, tumour markers and cortisol, 
oestradiol and progesterone. 
The NovoClone range of assays marketed by Novo 
BioLabs use alkaline phosphatase as label. This is assayed 
by enzyme amplification with release of a formazan dye 
measured kinetically at an absorbance of 492 nm. In this 
way the sensitivity of measuring the enzyme activity can 
be enhanced compared with conventional end-point 
measurement. At present thyroid hormone and gonadotrophin 
assays are available but no steroid assays. 
In addition to these systems which have been 
available for some time Medgenix and Sorin are in the 
process of releasing microtitre plate systems using HRP as 
label and TMB as chromogen. Both companies expect to 
release a wide range of assays over the next 2 years. 
1.11.2 COATED TUBES AND BEADS 
Boehringer Mannheim market the Enzymun-Test range 
where a monoclonal antibody to the analyte is linked to 
the reaction tube. HRP is used as the label with ABTS as 
the chromogen. A fully automated analyser is available 
for running up to 600 analyses on a range including 
thyroid and infertility hormones and tumour markers. 
Roche Diagnostics have had a similar range of assays 
available using HRP as label and monoclonal antibodies 
linked to beads. They are just about to change the 
chromogen from OPD to TMB. Hybritech also use coated beads 
with alkaline phosphatase as the enzyme. The assays may 
be carried out manually or on a fully automated system. 
1.11.3 HOMOGENEOUS ASSAYS 
The EMIT assays from Syva are based on enzyme 
inhibition or activation of the catalytic activity of 
the antigen-antibody complex. No separation of free and 
bound analyte is necessary. Assays are available for a 
variety of individual drugs in addition to assays for 
drug groups such as the cannabinoids and cocaine 
metabolites. In the hormone field assays for thyroid 
hormones have been available for some time, however the 
only steroid assay to date is one for cortisol in serum 
or plasma. In this assay the serum is pretreated with an 
undisclosed reagent for release of cortisol from 
endogenous binding protein. Two further reagents are 
added, one containing antibodies to cortisol and also 
substrate for the enzyme glucose-6-phosphate 
dehydrogenase (G6PDH). The other reagent contains a 
cortisol derivative labelled with G6PDH which binds to 
sites on the cortisol antibody not occupied by cortisol 
from the sample and reduces the enzyme activity by steric 
hindrance. The unbound enzyme conjugate remains active 
and converts NAD to NADH resulting in an absorbance 
change which is measured spectrophotometrically. The 
co-enzyme NAD reacts only with the bacterial G6PDH in the 
assay reagents so that endogenous G6PDH does not 
interfere. 
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1.11.4 MAGNETISABLE PARTICLE SEPARATION 
Serono Diagnostics market a series of EIAs where 
the sample is incubated with 2 mono clonal antibodies, one 
labelled with alkaline phosphatase and the other with 
fluorescein isothiocyanate (FITC). At .the end of the 
incubation anti-FITC linked to magnetisable particles is 
added and the bound complex precipitated on a magnet 
rack. After washing phenolphalein phosphate is added as 
substrate. The assay is stopped by the addition of sodium 
hydroxide and tubes read in a simple colorimeter. A range 
of peptide hormone assays are available in addition to a 
limited range of steroids mainly aimed at the infertility 
area. 
1.11.5 AUTOMATED SYSTEMS 
Several of the manufacturers are producing 
automated versions of their assays. In addition Abbott 
Diagnostics market a system based on fluorescence 
polarisation which is able to assay a variety of drugs and 
cortisol and oestriol. American Hospital Supply 
Corporation have a fluorometric ~~~ using a dry· reagent 
system. The range of assays available include drugs, 
thyroid hormones, HCG and cortisol. These systems need 
little manual intervention and are likely to become more 
popular in the future. 
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CHAPTER 2 
REAGENTS AND GENERAL METHODS 
2.1 GLASSWARE 
Glass borosilicate tubes 75 X 10, 75 X 12 and 100 X 
16mm whi ch were used throughout were, supplied by LIP 
Equipment and Services Ltd., Dockfield Road, Shipley, 
West Yorkshire 
2.2 SOLVENTS AND SOLIDS 
All chemicals were of analytical reagent grade 
obtained from BDH Chemicals Ltd (Poole, Dorset, UK) 
except where otherwise stated. 
2.3 BUFFERS 
These were prepared by diluting constituents in 
glass distilled water at room temperature, adjusting to 
the required pH and making up to 1 litre. 
PHOSPHATE BUFFERED SALINE (PBS) pH 7.2 
sodium chloride 
potassium dihydrogen phosphate 0.3M (40.8 glL) 
8.77 g 
33 mL 
adjusted to pH 7.2 with 2M potassium hydroxide 
(approximate'ly 5 mL) 
This buffer was stored at room temperature. 
2.3.1.1 RIA ASSAY BUFFER 
Immediately before use 0.1 g of gelatine was 
dissolved in 100 mL of PBS by heating in a water bath at 
50·C. The buffer was allowed to cool to room temperature 
and used for all stages of the assay. 
2.3.1.2 EIA ASSAY BUFFER 
1 g of bovine serum albumin (BSA) was dissolved in 
1 litre of PBS at room temperature and stored at 4·C. 
This was used for the immunoassay stage. 
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2.3.1.3 EIA WASH BUFFER 
0.1 mL of triton-Xl00 was added to 100 mL of PES 
and mixed until completely dissolved. This was then 
stored· at 4°C. 
O.1M SODIUM ACETATE/CITRIC ACID pH 6.0 
sodium acetate 
citric. acid O.lM to pH 6 
triton-X 
8.2 g 
(approximately 11 mL) 
mL 
This buffer, which was used for the assay of the 
HRP label, was stored at 4°C. 
2.4 STEROIDS 
CRYSTALLINE 
Crystalline steroids were used as supplied by 
Sigma Chemical Company Ltd. 
2.4.2 SOLUTIONS FOR USE IN THE STANDARD CURVE 
40 mg of 170HP was dissolved in 100 mL of 
absolute ethanol. 1 mL of this solution was diluted to 
100 mL with ethanol and mL of this solution further 
diluted to 250 mL with ethanol to give a concentration of 
1600 pg/0.1 mL. Further dilution was then carried out as 
~detailed in the individual Sections. 
2.4.3 SOLUTIONS FOR DETERMINATION OF SPECIFICITIES 
1 mg/mL solutions of each steroid were prepared 
in absolute ethanol. Appropriate dilutions were then made 
as detailed in Section 6. 
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2.4.4 RADIOACTIVE 170HP 
2.4.4.1 PRIMARY SOURCE 
[1,2,6,7- 3 HJ 170HP (specjfic activjty 56 Ci/mmol), 
supplied by ftmersham International, was stored at a 
concentration of 10 pCi/mL in 9:1 tbluene:methanol at 
4°C. 
2.4.4.2 3 H 170HP FOR USE IN RIA 
In the initial studies 300 pL of stock 
was transferred to a glass vjal and dried down, under 
vacuum, at 40°C. 20 mL of buffer containing gelatine was 
added and the vjal gently mj xed and allowed to stand for 
10 minutes before use to allow all the label to dissolve 
in the buffer. 
[25000 dpm, 67 
of stock label 
5000 cpm [8300 
This provided a count of 15,000 
pg/tube} • In the later stuc ies only 
was used per 20 mL of buffer which 
dpm or 22 pg/tube] 
cpm/tube 
100 pI 
yielded 
2.4.5.1 170HP LABELLED WITH HORSERADISH PEROXIDASE 
(170HP-HRP) 
This was prepared as described in detail in Chapter 3 
FIRST ANTIBODY 
3 different first antibodies were used at various 
stages of the project. The antigen in each case was 
17alpha-hydroxyprogesterone-3-0-carboxymethyloxime:BSA. 
They were supplied as follows: 
a) ftn antiserum raised in rabbits supplied by Steranti 
ftntisera Ltd., London in vjals of lyophiljsed material 
suffi ci ent for 1000 assay tubes. 
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b) Antiserum raised in sheep and kindly donated by 
Guildhay Antisera, Guildford, Surrey was supplied as neat 
serum. This was diluted 1 in 10 with PBS and stored frozen 
in aliquots at - 20°C. 
c) The third antiserum was supplied by BioClinical 
Services, P.O. Box 88, College Buildings, Cardiff, UK, 
lyophilised in vials sufficient for 1000 assay tubes. 
Appropriate dilutions of stock antiserum were 
prepared in assay buffer and stored at 4°C. 
SECOND ANTIBODY 
2 sources of second antibody were used: 
a) Donkey anti-rabbit antiserum was supplied by Benenden 
Antisera. The lyophilised material was reconstituted in 5 
mL of distilled water and stored at 4°C. 
b) DAMP-R and DAMP-S 
These are double antibody magnetisable particle 
preparations marketed by Serono Diagnostics Ltd. Woking, 
Surrey. The material is supplied at approximately 50 
mg/mL in buffer. Before use in the assays an appropriate 
volume of stock DAMP, equivalent to 40 mg, was pipetted 
into a 20 mL glass scintillation vial which was then 
filled with buffer, capped and mixed gently by inversion. 
The vial was then placed on a magnet. After allowing time 
for the magnetisable particles to settle the supernatant 
was aspirated. The DAMP was then washed 3 times with PBS 
allowing particles to settle on the magnet and aspirating 
the supernatant between each wash. The DAMP was then 
diluted to the appropriate concentration with PBS and 
stored at 4°C. 
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2.6 DEXTRAN COATED CHARCOAL (DCC) 
0.025 g of dextran was added to 100 mL of 
mixed gently. To this was added 0.25 g of 
PES and 
Norit A 
charcoal (Sigma Chemical Co. Ltd., Poole, Dorset, UK) and 
mixed by gentle inversion. The DCC was then stored at 4°C 
for at least 12 hours before use in the RIA. 
PREPARATION OF CHROMOGEN/SUBSTRATE 
O-PHENyLENEDIAMINE (OPD) 
0.507 g of OPD was dissolved in L of PES and 
the appropriate volume of hydrogen peroxide added 
immediately prior to use. 2 mL of this substrate solution 
was added to each tube and incubated for 1 hour at room 
temperature in the dark. 1 mL of substrate from each tube 
was transferred to another tube and the reaction was 
stopped by the addition of 600 pL of 2M sulphuric acid. 
It was noted that the OPD solution, with hydrogen 
peroxide added, rapidly turned yellow at room temperature 
necessitating the addition of the hydrogen peroxide 
immediately prior to use. 
TETRAMETHYLBENZIDlNE (TMB) 
A stock solution of TMB in dimethylsulphoxide (DMSO) 
was prepared and stored at room temperature in the dark. 
Immediately before use in the assay 750 yL cf the stock 
solution was added to each 100 mL of 0.1M sodium 
acetate-citric acid buffer (pH 6.0). After mixing by 
inversion the appropriate volume of hydrogen peroxide was 
added and the solution mixed and transferred to a 
dispenser. 
52 
2 mL of substrate was dispensed into each assay tube 
and incubated for the appropriate time. 1 mL of solution 
was transferred to a further tube and the reaction 
stopped by the addition of 500 pI of 2M sulphuric acid. 
2.8 MEASUREMENT OF ABSORBANCES 
The absorbances of all the solutions were measured 
using a Gilford Stasar III Spectrophotometer with flow 
through cell of path length 10 mm. The red colour of the 
OPD reaction was measured at 492 nm whilst the yellow 
colour of the TMB reaction was read at 450 nm. 
2.9 
2.9.1 
COLLECTION OF BIOLOGICAL SPECIMENS 
PLASMA 
Blood was collected into 2 mL tubes containing a 
crystal of lithium heparin either by venepuncture or by 
capillary collection from either the finger or the heel. 
The blood was then centrifuged and the plasma removed and 
stored at - 1SoC until assayed. 
2.9.2 
2.9.2.1 
SALIVA 
CHILDREN 
Where the children were old enough to collect the 
sample themselves they were instructed to rinse out the 
mouth with tap water prior to collecting whole saliva by 
dribbling into a 5 mL plastic tube. Where possible they 
were instructed to collect around 2 mL of specimen noting 
the date and time of collection on the tube. Saliva was 
collected in the morning, at lunch-time and in the 
evening, in each case before the medication was taken. 
Patients were requested to collect samples 
successive days, preferably at a weekend. 
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on 2 
2.9.2.2 BABIES 
In the case of babjes and small infants the mothers 
were taught how to collect the sample. A small wad of 
cotton wool was loosely wrapped around a wooden stick of 2 
mm diameter. By holding the cotton wool onto the stick 
with a finger and allowing the baby to suck on the finger 
saliva could be absorbed onto the cotton wool. When this 
became wet the wad was removed from the stick and inserted 
into the barrel of a 2 mL plastic syringe. The plunger was 
then inserted and the saliva squeezed out of the wad jnto 
a plastic collectjon tube. In this way, with practice, 
about 0.5 mL of saljva could be collected in 20 mjnutes. 
In the event of difficulty in collection, salivation 
could be stimulated by placing one drop of lemon juice 
under the tongue and waiting for a few seconds. 
All specimens were stored in a domestic freezer 
prjor to dispatch to the laboratory by First Class post. 
On receipt specimens were stored at 1SoC until 
analysis. 
2.9.2.3 PREPARATION OF SALIVA FOR ASSAY 
On the day of assay specimens were allowed to thaw 
at room temperature. They were then mjxed prior to 
centrifugation at 2500 x g for 10 minutes. Freezing 
precipitated the mucus and after centrifugation the clear 
supernatant could easily be pipetted using a positive 
displacement pipette. 
A cumulative record was kept of the salivary 170HP 
concentrations for each patient. If previous levels had 
been less than 2000 pmol/L then 200 yL of specimen, in 
duplicate, was extracted. However if higher levels had 
been measured 100 pL or, in some cases, 50 VL of sample 
was used and the volume made up to 200 pL with PBS. 
2.10 EXTRACTION OF BIOLOGICAL SAMPLES 
25 pL of plasma or 200 yL of neat or diluted saliva 
was pipetted into 75 x 12 mm glass tubes and extracted 
with 1 mL of diethyl ether using a SMI multivortex mixer 
for 10 minutes on setting 2 to 3. The aqueous layer was 
then frozen in a bath of dri-ice/methanol prior to 
decantation of the ether extract into fresh glass tubes. 
The ether was dried off by warming the tubes in a water 
bath at 40·C in a fume cupboard. 
2.11.1 RADIOIMMUNOASSAY 
To avoid the need for correction of counts for 
different quenching characteristics of solvents diethyl 
ether,used for the extraction of samples, was added to 
the standard tubes and absolute ethanol to all the other 
assay tubes. 
Stock standard (1600 pg/0.1 mL) was repeatedly 
diluted 1:1 to give a range of standards down to 12.5 
pg/0.1 mL in absolute ethanol. 0.1 mL of each standard 
was pipetted in triplicate into glass assay tubes. 
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All traces of ethanol were removed by drying tubes 
in a vacuum oven at 40'C. 100 fL of working antiserum was 
added to each tube followed by 100 yL of working 3 H 
170HP. 
When using the antibody supplied by Steranti 
Antisera Ltd., .the assay tubes were initially incubated 
at 37'C for 30 minutes prior to transferl~ to an ice 
bath for a further 2 hours incubation at 4°C. Later work 
with the Guildhay and Bioclinical Services antibodies 
avoided the initial incubation at 37'C and required only 
one incubation at 4'C for 2 hours. All assays could be 
left overnight at 4'C with no change in results. 
2.11.2 SEPARATION OF FREE AND BOUND LABEL 
500 pL of DCC in assay buffer was added to each tube 
and incubated for 15 minutes before centrifugation at 1500 
x g for 10 minutes. 
Supernatants were then decanted into micro 
scintillaticn vials. 3.5 mL of scintillation cocktail-T 
(BDH) was added and all tubes were counted for at least 3 
minutes in a Packard LSe. 
2.12 ENZYMEIMMUNOASSAY 
100 pl of the working dilution of antiserum was added 
to all tubes which were then incubated at room 
temperature for the time determined in the development of 
the assay. 100 pL of the working 170HP-HRP was then added 
and all tubes further incubated for the specified time. 
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Separation of free and bound 170HP-HRP was achieved 
by the addition of 1 mg of DAMP in PES and incubation at 
room temperature for 5 minutes. Racks were transferred to 
magnetic trays and allowed to stand for 3 minutes before 
decanting the supernatant to waste. The resulting pellet 
was washed the specified number of times before adding 2 
mL of substrate/chromogen to each tube and again 
incubating at room temperature for the specified time, 
mixing all the tubes by vortex every 5 minutes. 
for 
All the racks were then transferred 
5 minutes prior to removal of 
to a magnet 
1 mL of the 
supernatant for assay of the peroxidase as detailed above. 
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CHAPTER 3 
ASSAY OF PEROXIDASE 
Peroxidase was assayed using 2 different chromogens. 
The earlier work involved OPD for which temperature 
and time of incubation were investigated together with the 
optimum concentration of hydrogen peroxide. The rest of 
the project used TMB the optimum incubation conditions for 
which were investigated in some detail. 
OPD 
3.2.1 VOLUME OF HYDROGEN PEROXIDE 
Working solutions of substrate were prepared as 
detailed in Section 2.7.1 with 600, 700, 800, 900 and 
1000 pL of hydrogen peroxide per litre of solution. 2 mL 
aliquots of substrate were then added to 100 pL of HRP 
solutions (25 vg/L) and incubated for 60 minutes in the 
dark. The reaction was stopped with 2M sulphuric acid. 
Figure 2 shows an absorbance peak at 800 pL of 
hydrogen peroxide/litre of buffer. There was a rapid 
decrease in absorbance with higher concentrations of the 
substrate. 
3.2.2 TRITON-X IN SUBSTRATE BUFFER 
50 pL of triton-X was added to 50 mL of working 
substrate solution (800 pL of hydrogen peroxide/litre). 
100 pL aliquots of a 20 pg/L solution of HRP were 
pipetted into each of 12 assay tubes. To half the tubes 
substrate containing triton-X was added and to the other 
tubes substrate without the detergent. Individual tubes 
were then incubated for either 30 or 60 minutes at room 
temperature, 30·C or 37·C before stopping the reaction. 
Figure 2 Colour development with OPD and 
varying volumes of hydrogen peroxide 
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TABLE I EFFECT OF INCLUSION OF TRITON-X IN THE BUFFER FOR 
THE ASSAY OF PEROXIDASE 
Room 30·C 37·C 
temperature 
Absorbance at 492 nm 
Without triton-X 
30 minutes 0.53 0.45 0.19 
60 minutes 0.45 0.25 0.10 
With triton-X 
30 minutes 0.73 0.84 0.30 
60 minutes 0.93 0.46 0.19 
The inactivation of colour development with both 
increased temperature and time of incubation is seen in 
Table I in the absence of triton-X. The presence of the 
detergent was seen to stabilise the colour development at 
room temperature. There was a marginal increase in the 
colour produced when incubating at 30·C for 30 minutes 
but this protection was lost on longer incubation times 
at this temperature and at 37·C. 
EFFECT OF INCUBATION TIME 
Substrate solution containing 800 pL of hydrogen 
peroxide per litre and 0.1% triton-X was prepared. 2 mL 
of the substrate was added to 100 pL aliquots of 25 pg/L 
HRP. Tubes were then incubated in the dark at room 
temperature for 10, 20, 30, 40, 50 or 60 minutes stopping 
the reaction in the usual manner. 
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As can be seen from Figure 3 up to 40 minutes 
there was a proportional increase in absorbance with 
time. The rate of increase then decreased probably due to 
the increasing effect of the self-inhibition of peroxide 
product as well as exhaustion of the substrate. 
3.3 TMB 
3.3.1 EFFECT OF TRITON-X, INCUBATION TEMPERATURE, 
INCUBATION TIME AND VOLUME OF HYDROGEN PEROXIDE ON THE 
ASSAY OF PEROXIDASE USING TMB AS CHROMOGEN 
A 20 ~g/L solution of HRP was prepared and 100 pL 
aliquots of this solution were pipetted into each glass 
tube. 
750 pL of stock TMB (10 giLl was added to each 100 
mL of buffer. To half the total volume of buffer 
triton-X at a concentration of 0.1~ was added and the 
buffer mixed on a spiral mixer until complete dissolution 
had taken place. 
Volumes of 30% hydrogen peroxide varying from 50 to 
600 pL/100 mL of buffer were added immediately before use 
in the assay. 
The tubes were incubated either at room temperature 
or 37·C for either 30 or 60 minutes. 
The results are shown in Table 11 
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Figure 3 Time course of colour development 
using OPO as chromogen and incubating at 
room temperature in the dark 
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TABLE 11 EFFECT OF VOLUME OF HYDROGEN PEROXIDE, 
INCUBATION TEMPERATURE AND TIME AND PRESENCE OR ABSENCE 
OF TRITON-X ON THE ASSAY OF PEROXIDASE USING TMB AS 
CHROMOGEN 
Volume ()lL) of 
30% hydrogen 
peroxide/L 
Without triton-X 
Room 
Temp 
37°C 
30 min 
60 min 
30 min 
60 min 
With triton-X 
Room 
Temp 
37°C 
30 min 
60 min 
30 min 
60 min 
50 
1. SO 
1. 71 
0.74 
100 200 300 400 500 600 
Absorbance at 450 nm 
1 .49 1. 1 5 0 • 93 
1.27 0.95 0.75 
0.25 0.09 0.05 
0.76 
0.59 
0.04 
0.61 0.52 
0.47 0.41 
0.03 0.03 
0.31 0.10 0.04 0.03 0.02 0.02 0.02 
2.S5 
3·03 
1.00 
0.30 
2.S7 
2.99 
0.90 
0.49 
2.16 
2.05 
0.29 
0.11 
1. 75 
1.64 
0.14 
0.05 
1 .22 
1.10 
O.OS 
0.04 
0.99 
0.S3 
0.07 
0.04 
0.S1 
0.71 
0.06 
0.03 
As can be seen from Table 11 the use of a 
temperature of 37°C lead to the more rapid breakdown of 
the chromogen product as was also the case with the use 
of volumes of hydrogen peroxide in excess of 100 pL/L. 
The effect of the triton-X was to double the 
colour, presumably by giving stability to the coloured 
product. Even at the higher concentrations of hydrogen 
peroxide the same proportional increase was seen. 
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The results show that either 50 ~L or 100 ~L of 
hydrogen peroxide could be used with similar effect. 100 
FL of the 30% hydrogen peroxide was used in subsequent 
experiments since the volume of working substrate often 
required was 100 mL and 10 pL could be more accurately 
and precisely pipetted than 5 pLo 
TIME COURSE OF COLOUR DEVELOPMENT 
22 tubes were prepared containing 100 pL of 20 ng/L 
HRP and 2 mL of working substrate was added rapidly to' 
each tube. At timed intervals from 4 to 15 minutes 1 mL 
of 2M sulphuric acid was added to stop the colour 
development in duplicate tubes and solutions read 
immediately at 450 nm. 
Results: 
Figure 4 shows there is a steady increase in colour 
development which, although it begins to plateau around 
14 minutes would still require stopping of the reaction 
in each tube at the same rate as the substrate was added 
to the tubes in order to avoid drift in the results. 
STABILITY OF STOCK TMB 
100 ~L of 30% hydrogen peroxide was added to 1L of 
PBS containing 0.1% triton-X. After mixing 6 mL of this 
solution was dispensed into glass vials and 45 pL of 
stock TMB in DMSO, which had been stored in the dark for 
periods from week to 1 year, was added. After further 
mixing 2 mL of each solution was transferred to tubes 
containing 100 ~L of a 25 ~g/L HRP solution. 
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Figure 4 Time course of colour development at 
650 nm using TMB as chromogen 
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All tubes were incubated at room temperature for 20 
minutes. 1 mL of 2M sulphuric acid was added to each 
tube and after mixing all tubes were read at 450 nm. 
Results: 
All tubes had absorbances between 2.00 to 2.24 
showing no evidence of decreasing with length of storage. 
So the stock TMB would appear to be stable for at least 
1 year when stored at room temperature in the dark. 
STABILITY OF WORKING SOLUTION OF 
CHROMOGEN/SUBSTRATE 
Working substrate solution was prepared as detailed 
in Section 2.7.2 with the addition of 0.1% triton-X to 
the buffer. 2 mL of this solution was added in duplicate 
to tubes containing 100 pL of a 25 ~g/L HRP solution. The 
tubes were mixed and incubated for 5 minutes at room 
temperature. 1 mL of 2M sulphuric acid was added to each 
tube prior to reading the absorbance at 450 nm. 
The rest of the substrate was stored in an amber 
bottle in a dark cupboard and at intervals duplicate 2 mL 
aliquots were taken for incubation with HRP as above. 
The results listed in Table III show there was an 
initial fall in absorbance in the first 15 minutes but 
then the overall absorbance remained fairly constant 
however the background absorbance rose steadily with the 
development of blue colour visible by eye by 2 hours. 
From these results it appeared preferable to prepare the 
working substrate/chromogen 15 minutes before it was 
required but to then use it within 2 hours. 
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TABLE III STABILITY OF WORKING TMB/SUBSTRATE SOLUTION 
Time from preparation 
of solution (minutes) 
o 
15 
30 
50 
75 
90 
120 
160 
Absorbance at 450 nm 
with HRP 
0.46 
0.42 
0.42 
0.41 
0.40 
0.38 
0.38 
0.38 
blank 
0.002 
0.002 
0.003 
0.004 
0.005 
0.010 
0.012 
0.014 
3.3.5 EFFECT OF ANILINONAPHTHALENE SULPHONIC ACID 
(ANS), MERTHIOLATE AND 
PEROXIDASE ASSAY 
SODIUM SALICYLATE ON THE 
In the Introduction (Section 1.8.1) the need for a 
blocking agent in direct hormone assays was discussed. 
To investigate the effect of 3 commonly used blocking 
agents on the HRP activity 10 g/I, solutions of ANS, 
merthiolate and sodium salicylate were prepared in PBS 
and these were then double diluted to give 
concentrations down to 0.2 g/1. 
100 y1 of each solution was added to 100 yL of HRP 
(20 ng/L) and 2 mL of working substrate and the tubes 
incubated for 20 minutes at room temperature. The 
reaction was stopped with 2M sulphuric acid and the 
tubes were then read at 450 nm. 
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The results (Table IV) show that all 3 of these 
blocking agents inhibit the peroxidase. 2 mg/tube is 
the usual mass of salicylate necessary for displacing 
hormones from binding proteins and this was seen to 
reduce absorbance by 19% but still result in an 
acceptable absorbance of 1.15. 0.02 mg/tube of ANS was 
sufficient to almost totally inhibit the peroxidase 
activity whereas a similar quantity of merthiolate 
resulted in a 71% reduction in absorbance. It would, 
therefore, appear that only sodium salicylate could be 
used as a blocking agent in this assay system. 
TABLE IV INHIBITION OF PEROXIDASE ACTIVITY BY SODIUM 
SALICYLATE, ANS AND MERTHIOLATE 
Mass of inhibitor Absorbance at 450 nm 
mg/tube sodium ANS merthiolate 
salicylate 
0 1.35 1.35 1.35 
0.02 1. 31 0.10 0.39 
0.04 1.30 0.01 0.05 
0.08 1.27 0.01 0.05 
0.16 1.27 0.01 0.05 
0.31 1.24 0.01 0.05 
0.62 1.22 0.01 0.05 
1.25 1.19 0.01 0.05 
2.5 1.15 0.01 0.05 
5.0 precipitated on 0.01 0.05 
10.0 addition of acid 0.01 0.05 
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CHAPTER 4 
170HP-HRP CONJUGATION 
4.1. STEROID DERIVATIVES 
Considerations for production of enzyme labelled 
steroids are similar to those necessary for the generation 
of antibodies to the steroids (Landon et al (1974». 
Problems arise from the small size of the steroid 
molecule and the subtle changes in structure which lead 
to profound changes in biological activity. Tt is 
therefore necessary to attach the enzyme to the steroid 
molecule by a linking group covalently inserted between 
the enzyme and a hydroxyl- or keto- group on the steroid 
molecule. Derivatives such as hemisuccinates, 
chlorocarbonates and O-carboxymethyl-oximes 
described by Kellie et al (1974). The precise 
have been 
position of 
the group through which the link is made to the steroid 
is important in considering the specificity of the assay 
and linkage through carbon-3 of the A ring is common as 
this is the part of the corticosteroid molecule distal 
from the area of most influence on biological activity. 
4.2 CONJUGATION OF ENZYME TO STEROIDS 
Conjugation can be achieved by first reacting 
succinic anhydride with hydroxyl groups on the steroid 
to form hemi-succinates, or ketone or aldehyde groups 
with carboxymethyloxime to form O-(carboxymethyl)oximes 
so introducing carboxyl groups (Erlanger et al (1959», 
through which the enzyme can then be conjugated to the 
steroid. A number of conjugation methods are available 
(Tijssen (1985» but the most commonly used procedures 
for steroids are: 
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(i)- the mixed anhydride method 
(ii) carbodiimide method (CDI) 
The CDr method has been used to conjugate 
glycoamylase to testosterone (Tateiski K et al (1975», 
beta-galactosidase to oestradiol (Exley and Abuknesha 
(1978» and alkaline phosphatase to cortisol (Ogihara 
(1977) and Kobayashi et al (1978». The conditions of the 
conjugation are simple but yields of only 20% may be 
achieved (Erlanger (1980». 
The mixed anhydride method (Erlanger et al (1959» is 
a simple direct method where a carboxyl group is 
converted to an acid anhydride prior to reaction with the 
amino groups of the enzyme. Usually 10 - 20 molecules of 
hapten are added per molecule of enzyme (Ra~owski et al 
(1977». O'Sullivan et al (1978) suggested that this 
ratio of hapten to enzyme was necessary because of 
possible damage to the hapten during the cross-linking 
process or because of it becoming buried in the interior 
of the enzyme. 
Numazawa et al (1977) used this method to prepare 
oestradiol-HRP and Joyce et al (1977) to prepare 
progesterone-HRP. Yields vary but Munro and Stabenfeldt 
(1984) with an initial ratio of 20 molecules of 
progesterone to 1 of HRP obtained an enzyme incorporation 
ratio of 1.5:1 with an overall yield of 85 - 95% 
4.3 MIXED ACID ANHYDRIDE REACTION 
The reaction is carried out in 2 stages. In stage 1 
the steroid derivative and a chlorocarbonate are dissolved 
in an anhydrous solvent at O·C and a tertiary amine added 
to remove hydrogen chloride and form the mixed anhydride. 
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The reaction takes a few minutes and stability is good at 
low temperatures. Figure 5 shows the chemistry of the 
reaction. 
In stage 2 the acid anhydride is decomposed by the 
E-amino groups of lys ine resi dues in the enzyme. As the 
enzyme is not soluble in anhydrous solvents it is first 
dissolved in water. However this leads to instability of 
the mixed anhydride so the reaction is not able to proceed 
to completion and the final reaction mixture contains 
enzyme molecules variously 
degrees as well as a 
steroid derivative. 
conjugated and 
large proportion 
to 
of 
differing 
unreacted 
This unreacted steroid can be largely removed from 
the mixture by dialysis against distilled water at 4'C for 
2 to 3 days. Further purification can then be carried out 
by gel filtration using a cross-linked dextran (Sephadex 
G25) as the stationary phase. In this technique the small 
steroid molecules penetrate the pores of the Sephadex and 
are retained whilst enzyme molecules, which are too large 
to enter the support, are rapidly eluted from the column. 
Because of the similar molecular weight of HRP and 
170HP-HRP these species were unlikely to be separated by 
this technique and the mixture would require further 
purification by affinity chromatography. 
For affinity chromatography antibody to the 
steroid is con~ugated to a solid phase support. On adding 
the mixture of steroid-HRP and unreacted HRP to the 
column, the conjugate binds to the antibody on the column 
whilst the HRP is eluted. A change in the mobile phase 
buffer pH liberates the conjugate. 
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I 
PREPARATION OF 170HP-HRP 
APPARATUS FOR INCUBATION AT -15'C 
As a refrigerated incubation bath was not available 
it was necessary to construct a reaction vessel 
from available equipment. This was, in any case, in 
keeping with one of the aims of this project to use 
methodology involving the 
instrumentation, 
minimum of specialised 
The reaction vessel consisted of a 1 5 mL pyrex 
Quickfit tube with a small magnetic stir-bar. The tube 
was suspended in a small beaker containing 50~ 
ethanediol. This in turn was placed in a larger beaker 
surrounded by polystyrene. The whole apparatus stood on 
top of a magnetic stirrer which was used at low speed. 
For the first hour of the incubation crushed dri-ice was 
placed in the larger beaker and this was replaced as 
necessary such that the temperature of the ethanediol was 
kept below -15'C, as measured with a probe attached to a 
digital thermometer. The ethanediol beaker was then 
replaced with a beaker of water and crushed ice' for 
incubation at O·C. 
PREPARATION OF 170HP-HRP CONJUGATE 
HRP was coupled to the 3-CMO derivative of 170HP 
using a modification of the mixed anhydride method 
-- --
described by Van Weemen etal (·1978) 
A solution of 6.05 mg of 170HP-3-CMO and 2.25 ~L of 
N-methylmorpholine in 300 pL of N,N-dimethylformamide 
(DMF) was cooled to -15'C in a freezer. The tube was 
transferred to the ice bath and 2.25 of 
isobutylchloroformate was added. The solution was stirred 
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for 3 minutes using a magnetic flea and mixer and added 
dropwise to a precooled solution (O·C) containing 30 mg 
of HRP in 300 pL of distilled water and 2.25 pL of DMF. 
The mixture was stirred at -15·C for 60 minutes and then 
for a further 120 minutes at O·C. 
3 mg of sodium bicarbonate was added and the contents 
of the tube transferred to a dialysis bag which was 
immersed in L of distilled water and gently stirred for 
24 hours in a cold room at +4·C. The dialysis was repeated 
twice further changing the water each time. 
A 1.7 X 36 cm column was filled with hydrated 
Sephadex G25 and the reaction product was then purified by 
transferring the dialysate to the top of the column and 
eluting with PES. In early attempts to prepare 170HP-HRP 
conjugate an automated fraction collector was used 
together with spectrophotometric monitoring of the 
eluate. However the intensity of the absorption peak as 
the HRP passed was so high that even with the sensitivity 
reduced to a minimum the peak was still well off the top 
of the chart. Therefore subsequently the eluate was 
collected in 2 mL fractions without monitoring. 
Whilst affinity chromatography could have been used 
for further purification this was felt to be unnecessary 
as all unreacted steroid should have been removed and 
unreacted HRP would be removed during the wash step of the 
ErA. The eluates were stored at -1S·C. 
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4.4.3 CHARACTERISATION OF 170HP-HRP CONJUGATE 
Rajkowski et al (1977) when conjugating HRP to 
testosterone included a small amount of tritiated 
testosterone-3-CMO in the reaction mixture to monitor 
recovery in the chemical reaction. In the present project 
no tritiated 170HP-3-CMO was available commercially. They 
also determined the ratio of hapten molecules bound to 
each molecule of HRP by scanning solutions on a recording 
spectrophotometer. 1 mg/mL solutions of 170HP-3-CMO and 
170HP in ethanol and HRP and 170HP-HRP in PBS were 
prepared and scanned using a Phillips 
Absorbance peaks at the following 
observed: 
Spectrophotometer. 
HRP 
170HP-oxime 
170HP 
broad peak 
170HP-HRP conjugate 
wavelengths 
250 - 270 nm 
248 - 250 nm 
244 - 248 nm 
246 - 250 nm 
were 
The 170HP-HRP conjugate absorbance peak coincides 
with both the peaks of 170HP and 170HP-oxime such that it 
was not possible to calculate the incorporation ratio 
from spectrophotometric data. 
In order to calculate the ratio the mass of 170HP was 
measured using the RIA method detailed in the General 
Methods Chapter (2.10.1) and the HRP activity was measured 
by the method detailed in Section 2.7.1 with OPD as 
chromogen. 
Table V shows the results of these assays for each 
fraction of the eluate. The incorporation ratio of the 
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TABLE V RATIO OF THE NUMBER OF MOLECULES OF 170HP CONJUGATED TO EACH MOLECULE OF 
CALCULATED BY MEASURING THE MASS OF 170HP PER ML OF NEAT ELUATE USING RIA AND 
MASS OF ENZYME FROM ITS ACTIVITY. 
HRP 
THE 
RIA mass of 170HP/mL mass of IlRP/mL 
of eluate of eluate 
Ratio of mols of 
170HP:HRP 
Fraction 
No. 
4 
5 
6 
7 
8 
9 
ug 
5.7 
56.6 
87.7 
35.3 
18.4 
16.5 
Molecular weight 
Molecular weight 
of 
of 
nmol ug nmol 
14 
140 96.8 2.4 
217 567.7 14.2 
87 219.3 5.5 
46 119.9 3.0 
4 1 43.2 1.1 
170HP-3-(0-carboxymethyl)oxjme = 403.5 
HRP assumed to be 40,000 
All concentratjons relate to 1 mL of neat conjugate solution 
58 
15 
16 
15 
38 
number of molecules of 170HP bound to each enzyme molecule 
was found to vary between 58: 1 for fraction 5 and 15: 1 
for fractions 6 and 8. Joyce et al ( 1978) found that 
low molar incorporation ratios, in their case of 2: 1 , 
improved the lower limit of sensitivity in assays for 
progesterone and oestrac io1- Bearing this in mind 
fraction 6 was used for early development of the present 
ETA. 
4.5 STABILITY OF 170HP-HRP WORKING SOLUTIONS AT 4"C 
To determine the stability of working strength 
solutions of 170HP-HRP in PBS a 1 in 1000 dilution of the 
conjugate was prepared. 150 ~L ali~uots of this solution 
were prepared and half the total number frozen at - 18°C. 
The remaining tubes were stored at 4°C. 
3 mL aliquots of freshly prepared PBS/BSA were 
dispensed into glass assay tubes and stored at 4°C for the 
duration of the stability study. At frequent intervals one 
aliquot each of the frozen and refrigerated 1 : 1 000 
solutions were placed at room temperature for an hour. 100 
pL of each aliquot was then added to separate tubes 
containing 3 mL of PBS/BSA at room temperature so forming a 
1 :30000 solution. 20 pL of each dilution in triplicate was 
then transferred to assay tubes and 2 mL of TMB/hydrogen 
peroxide added. Tubes were mixed and incubated for 3 
minutes at room temperature prior to addition of 1 mL of 2M 
sulphuric acid. The absorbance at 450 nm was measured. 
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Results: 
Table VI shows the ratio of the absorbance at 450 nm 
for each tube prepared from 170HP-HRP stored at 4°C 
relative to the absorbance of the aliquot stored at _20°C. 
The use of the ratio provided a comparable figure as 
there was some fluctuation in the absorbances from day to 
day. This was probably due to the need to make a Cl ilution 
of the steroid solution each day before the HRP assay and 
reflects the changes in setting of the ad~ustable 
displacement pipette used. Also the room temperature 
could vary by several degrees from day to day. 
In part A of the study the apparent activity of the 
HRP was seen to rise over the first day of storage at +4°C 
and the increased absorbance with respect to the frozen 
aliquot was maintained for between 21 and 30 days. 
Part B investigated the effect at weekly intervals 
to 7 weeks post preparation of solutions. This reflected 
the earlier results and suggests that 170HP-HRP at 1 :1000 
may be stored for at least 4 weeks at +4°C for optimum 
performance in the EIA. Beyond this time the activity 
decreases at a variable rate (ratio 0.42 at 46 days in A, 
0.66 at 49 days in B) requiring storage at - 18°C for long 
term use. 
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TABLE VI RATIO OF ABSORBANCES OF ALIQUOTS OF 170HP-HRP 
SOLUTIONS STORED AT + 4"C TO SOLUTIONS STORED AT - 18"C 
Days from prep Mean Absorbance Ratio of 
of 1: 1 000 at 450 nm Absorbance at 
solutions + 4"C - 18° C +4°C : -18°C 
A 0 1.86 1.86 1.00 
1 1.94 1. 71 1.13 
2 2.08 1.83 1.13 
4 2.00 1.66 1.20 
5 1.95 1.73 1.13 
7 2.17 1.75 1 .24 
9 2.02 1.86 1.09 
1 1 2.01 1.76 1 .14 
14 2.17 1.97 1.10 
16 2.19 1.92 1 .14 
21 2.12 1.86 1.14 
30 2.01 2.09 0.96 
46 0.87 2.07 0.42 
B 14 2.43 2.29 1.06 
21 2.72 2.71 1.00 
28 2.87 2.92 0.98 
35 2.60 2.74 0.95 
42 2.24 2.85 0.79 
49 1.52 2.29 0.66 
4.6 EFFECT OF USE OF SULPHURIC ACID AND HYDROCHLORIC 
ACID AT VARIOUS CONCENTRATIONS AS REAGENT FOR STOPPING THE 
REACTION 
So far the colour development reaction had been 
stopped by the addition of 2M sulphuric acid. The use of 
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both this and hydrochloric acid at various strengths was 
investigated by using 1 mL of a dilution of 1 :100,000 
170HP-HRP in PBS with 20 mL of prepared TMB/hydrogen 
peroxide. After incubating for 3 minutes the reaction was 
stopped by the addition of 10 mL of 2M sulphuric acid or 
M, 4M, 5M or 6M hydrochloric acid. 
Results are shown in Table VII. The stability of the 
stopped reaction is important as large batches of tubes 
may take up to 30 minutes to read in a spectrophotometer. 
When the reaction was stopped with the strengths of acids 
tested absorbances within ± 2% of the original reading 
were obtained for up to 1 hour except for lM hydrochloric 
acid. Therefore only when longer standing times were 
anticipated would the use of either 2M sulphuric acid or 
4M hydrochloric acid be preferable both giving absorbances 
within ± 4% up to 3 hours after addition of the acid. 
TABLE VII STABILITY OF COLOUR AFTER REACTION STOPPED WITH 
2M SULPHURIC ACID OR lM, 4M, 5M AND 6M HYDROCHLORIC ACID 
Time from stopping Ratio of absorbance at the time 
of reaction relative to absorbance at time zero 
(minutes) sulphuric hydrochloric acid 
2M 1M 4M 5M 6M 
15 0.99 1.00 1 .00 1.00 1.00 
30 0.98 1.02 1.00 1.01 1.01 
60 0.98 1.04 1 .00 1.01 1.01 
90 0.97 1.06 1.02 1.03 1.03 
120 0.96 1.07 1 .02 1.05 1.04 
150 0.96 1.03 1.09 1.09 
180 0.96 1.03 1.09 1.09 
240 0.95 1.12 1.12 
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4.7 TIME COURSE OF COLOUR DEVELOPMENT 
A series of 24 tubes containing 20 pL of a 1:80,000 
dilution of 170HP-HRP conjugate was prepared. 2 mL of 
working substrate was added to one tube and the solution 
immediately transferred to a cell of 1 cm pathlength and 
the absorbance at 650 nm recorded at minute intervals in 
a Philips PU8720 UV/VIS scanning spectrophotometer. 
2 mL of working substrate was added to the remaining 
tubes which after mixing were incubated at room 
temperature. At 1 minute intervals 1 mL of 2M sulphuric 
acid was added to stop the reaction. All tubes were then 
read in the spectrophotometer and the absorbances at 450 
nm and 405 nm recorded. The results are shown in Figure 6. 
The blue colour read at 650 nm showed a linear 
increase for about the first 10 minutes before the curve 
begins to plateau at the absorbance of 1.2. In the case 
of the stopped reaction the absorbance showed a linear 
relationship to approximately 12 minutes before the curve 
tended towards a plateau around an absorbance of 2.6. 
There appears to be a 2 minute discrepancy between 
the point of flattening for the reaction with and without 
stopping with acid. However it was not practically 
possible to initiate the reaction in all the tubes at the 
same moment and also the unstopped tube was in the beam 
of the tungsten lamp for the whole of the 20 minutes it 
was scanned which may have lead to a loss in absorbance. 
However the formation of the yellow colour can be seen to 
double the measured absorbance. 
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Figure 6 TIme course of colour development at 
3 wavelengths using TMB as chromogen 
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The absorbance at 405 nm was investigated since a 
prototype of a commercial kit using the same TMB 
chromogen became available shortly before the completion 
of this project. This assay was an EIA based on a 
microtitre plate using HRP labelled monoclonal antibodies 
for assay of a number of hormones and tumour markers. In 
order to extend the working range of this commercial 
assay the plate reader is programmed to read all wells at 
405 and 450 nm. Where the absorbance at 450 nm exceeds 3 
Absorbance units the reading at 405 nm is used to 
calculate high results. The above experiment showed a 
linear increase in absorbance at 405 nm for at least 20 
minutes. In the current project, as the labelled molecule 
is the steroid-oxime, reading at the dual wavelength 
might improve the sensitivity of the assay. 
CHAPTER 5 
5 SEPARATION OF FREE AND BOUND LABELLED 170HP 
5.1 SEPARATION USING ENZACRYL FEO-M 
Early work involved the use of Enzacryl FED-M, a 
ferric oxide/cellulose particle distributed by 
Ltd. The gamma- globulin of horse-anti-rabbit 
(Benneden) was linked to the Enzacryl FED-M 
method of Nye et al (1976). 
Koch-Light 
antibody 
using the 
The prepared magnetisable particle/second antibody 
reagent was washed with PBS allowing the particles to 
sediment on a magnet and decanting the 
between each washing. Reagents from a 
supernatant 
commercially 
available assay for cortisol were used to test the 
efficiency of the separation system. These reagents 
consisted of Il'r labelled cortisol and rabbit antibody 
raised against 3-0CO-cortisol. 11$'r was used as the tracer 
as the bound fraction would then be in the pellet and 
thus easier to count. Tubes were set up as follows: 
100 pL 125'r cortisol 
200 pL anti-cortisol antibody 
The incubaticn was carried out for 1 hour at 37°C. 
rn the meantime solutions were prepared containing 
7.5, 5, 4, 3, 2 and 1 mg Enzacryl-second antibody per 200 
pL of PES. After the immunoassay incubation 200 pL of 
each Enzacryl solution was pipetted into duplicate assay 
tubes and incubated for 5 minutes before carrying out the 
following procedure: 
A) Vortexed, incubated 10 minutes, and the rack placed on 
the magnet 
B) As for A) but vortexed again after the initial 10 
minutes and incubated a further 15 minutes. 
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c) As for B) with additional vortex and 15 minutes 
incubation 
D) As for C) with additional 15 minutes incubation. 
At the end of each complete incubation tubes were placed 
on a magnetic rack and allowed to sediment for 5 minutes. 
The supernatant was discarded and the pellets counted. 
Results 
TABLE VIII PERCENTAGE OF 1251 CORTISOL BOUND TO ANTISERUM 
FOLLOWING INCUBATION AND ADDITION OF MAGNETISABLE SECOND 
ANTIBODY WITH VARYING WASH CONDITIONS. 
Incubation 
and wash 
conditions 
A 
B 
C 
D 
Enzacryl-anti-rabbit antibody 
7.5 5.0 4.0 3.0 
25.7 
30.1 
31.2 
33.6 
18.0 
25.9 
23.7 
24.5 
22.7 
23.1 
25.7 
23.8 
13.9 
14.7 
17.4 
18.7 
mg/tube 
2.0 
13.7 
16.0 
15.4 
16.9 
The binding in the commercial assay using 
antibody separation was around 60%. As can be seen 
Table VIII the maximum binding of 33.6% was achieved 
1.0 
10.3 
11.0 
12.2 
14.2 
second 
from 
with 
the use of 7.5 mg of Enzacryl with a one hour incubation. 
The binding could probably be increased by the use of a 
higher concentration per tube but this would increase the 
cost of the assay. The erratic results seen 
due to the irregular size of the particles 
al (1976) had milled their particles 
equipment was not available. 
are 
used. 
but 
probably 
Nye et 
similar 
Other magnetisable particles are available such 
as Dynabeads supplied by Dynal (UK) Ltd, New Ferry, 
Wirral, however Serono Diagnostics started marketing a 
ready to use anti-rabbit antibody linked to ferric oxide 
particles (DAMP-R) about this time and it was decided to 
use this reagent for the project, since previous 
experience with Serono products had shown them to be 
consistently reliable. 
5.2 DETERMINATION OF MASS OF DAMP-R REQUIRED PER 
ASSAY TUBE TO EFFECT SEPARATION 
The mass of DAMP-R required/tube was assessed using 
3 H 170HP and the Steranti anti-170HP using the 
incubation protocol as for the regular RIA. (Section 
2.10.1) but using the DAMP-R in place of the dextran 
coated charcoal. Standard solutions of 170HP of 0 and 400 
pg/0.1 mL were used to give an indication of the binding 
that would be available in the immunoassay. DAMP-R was 
supplied at a concentration of 54.3 mg/mL and this was 
diluted to give concentrations of 10, 5, 4, 3, 2, and 
0.5 mg/mL. 0.5 mL of each was added in duplicate to tubes 
after the immunoassay incubation. The incubation 
conditions for the DAMP-R were as recommended by the 
manufacturer which was an initial 5 minutes equilibration 
followed by vortexing and a further incubation for 10 
minutes at ambient temperature (approximately 20·C). All 
tubes were then placed on a magnetic tray such that the 
bottom of each tube was in contact with a permanent 
magnet. They were allowed to stand for 10 minutes before 
decanting the supernatant into pi co-scintillation vials 
(volume capacity 6 mL) and counting in the LSC. This count 
would reflect the free label, the bound being attached to 
the magnetic phase. 
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Results 
TABLE VIII ~~SS OF DAMP-R REQUIRED FOR SEPARATION USING 
TRITIATED 170HP AS LABEL 
Total count added/tube = 19520 cpm 
DAMP 170HP % 170HP % Difference 
mg/tube o pg free 400 pg free in % free 
0-400 pg 
5.0 12030 61.6 14200 72.7 11.1 
2.5 12680 65.0 14510 74.3 9.3 
2.0 12830 65.7 14720 75.4 9.7 
1.5 13150 67.4 14970 76.7 9.3 
1.0 13350 68.4 15110 77 .4 9.0 
0.5 13880 71.1 15330 78.5 7.4 
0.25 14261 73.1 15720 80.5 7.4 
1 mg of DA~lP-R/tube gave 68.4% free for 0 pg and 
77.4% free for 400 pg being equivalent to 31.6% and 
22.6% bound respectively. The difference in binding for 
the 2 standards was similar to using 2.5 mg/tube but with 
improved economy. 
5.3 EFFECT OF DAMP-R ON HRP ASSAY 
Since the DAMP-R as supplied was intended for use in 
RIA's the effect of its presence in the measurement of HRP 
activity was investigated. 
100 pL of a 25 ng/mL solution of HRP in PBS was 
incubated with either A. 100 pL of PBS or B. 100 pL of 
DAMP-R (1 mg) (pre-washed with its own volume of buffer 
to remove fine particles) and 2 mL of OPD/hydrogen 
peroxide for 1 hour in the dark as detailed in Sections 
2.7.1 and 2.8. 
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Results Figure 7 shows a blank absorbance of 0.35 for the 
washed solution and a blank of 0.55 without washing. It 
was noted that fine particles of magnetisable material 
were on the surface of the liquid in the tubes and it is 
likely that this is the cause of the increased background 
absorbance. As can be seen from the Figure the effect was 
less pronounced at the higher standard values. 
5.4 GENERAL SEPARATION PROCEDURE 
The DAMP-R was best pipetted with a multipettor using 
a syringe type barrel. Multipettors with valves should be 
avoided as the DAMP deposits around the edges of the 
valve leading to occlusion of the valve in time. 
As a result of the above experiments the following 
procedure was used as the separation step: 
500 pL DAMP-R (2 mg/mL in PES) was added to all 
tubes which were then vortex mixed. 
All tubes were allowed to stand at room temperature 
for 5 minutes. They were then vortexed and incubated for 2 
periods of 10 minutes with vortexing at intervals. 
Tubes were then transferred to Serono Diagnostics 
racks which have a small permanent magnet directly under 
each tube. 
The tray was left to stand on the magnet for 3 
minutes after which the supernatant was discarded. 
1 mL of PES containing 0.1 % triton-X was added and 
all tubes mixed on a multi vortex mixer using four to five 
3 second mixes to ensure adequate washing. 
The tray was again placed over the 
allovTed to sed iment for 5 minutes. 
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magnets and 
Figure 7 Effect of DAMP-R on the HRP assay 
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Supernatants were then discarded to waste and the 
rack left inverted on paper towelling to drain for 8 
minutes. The triton-X present ensured rapid and efficient 
draining. Any droplets of supernatant remaining in the 
tubes could be removed using cotton wool swabs. 
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CHAPTER 6 
ASSAY DEVELOPMENT 
6.1 TITRATION OF 170HP-HRP CONJUGATE 
Fraction 6 of the 170HP-HRP conjugate was selected 
first as this had the highest enzyme activity as shown in 
Section 4.4.3 with an incorporation ratio of 15:1 
Solutions of 170HP at concentrations of 0, 500, 
1000, 2000 ng/mL were prepared in absolute ethanol as 
detailed in 2.4.2 
Neat 170HP-HRP conjugate solution was diluted in PBS 
to give solutions ranging from 1:1000 to 1 :64000. 100 pL 
of each of these solutions was added to the dried down 
170HP standards and all the tubes were incubated at room 
temperature for 19 hours. 500 pL of DAMP-R (2 mg/mL) was 
added to each tube and treated as in the general 
separation protocol (Section 5.2) The HRP was measured 
using OPD as chromogen (Section 2.7.1). 
Results depicted in Figure 8 as a spline fit show that 
the highest dilution of 170HP-HRP which would give a 
clear difference in absorbances for each of the standards 
in the range of the assay was 1:20,000. This dilution was 
therefore chosen for subsequent experiments. 
6.2 
6.2.1 
INCUBATION TIMES FOR THE IMMUNOASSAY 
EFFECT OF ONE STEP INCUBATION OF LAllEL, ANTIBODY 
AND STANDARD COMPARED WITH PREINCUBATION WITH ANTIBODY 
100 rL aliquots of standard solutions of 170HP in 
absolute ethanol (0 to 400 pg/O.l mL) were dried down in 2 
sets of glass tubes. 
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Figure 8 Titration of 170HP-HRP with assay antibody 
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To one set 100 yL each of 170HP-HRP and antibody were 
added and the tubes were incubated for 1 hour at room 
temperature. 
To the second set 100 pL of antibody was added and 
incubated for 30 minutes at room temperature prior to the 
addition of 100 pL 170HP-HRP. The main incubation was for 
60 minutes at room temperature. 
500 yL of DAMP-R was then added as in Section 5.5 
and the peroxidase activity measured using OPD as 
chromogen. 
Results: As can be seen from Figure 9 the preincubation 
with antibody resulted in a larger fall in absorbance at 
low concentration and this would give better preqision. 
6.2.2 VARYING TIMES FOR PREINCUBATION WITH ANTIBODY 
4 sets of duplicate tubes containing 7 standards 
ranging in concentrations from 0 to 400 pg/O.l mL were 
prepared as in Section 2.4.2. Also 4 sets of quality 
controls were extracted and dried down as in Section 2.9. 
100 pL of antibody was added to each set of tubes at 
intervals of 15 minutes. 1 hour later 100 pL of 170HP-HRP 
was added to each tube and the incubation continued for 1 
hour at room temperature. In this way preincubation times 
of 15, 30, 45 and 60 minutes were achieved with a further 
main incubation of 60 minutes in each case. 
Results: These are shown in Figure 10 as a spline fit 
together with the results for the quality controls 
samples in Table IX. The QC results for a preincubation of 
30 minutes gave values closest to those expected. 
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Figure 9 Comparison of binding achieved 
0) a pre-incubation with antibody compared with 
b) a combined incubation with antibody and 170HP-HRP 
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Figure 10 Varying times of pre-incubation with antibody 
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TABLE IXB VALUES FOR QUALITY CONTROL MATERIAL ASSAYED 
FOR 30 MINUTES PREINCUBATION WITH ANTIBODY AND VARYING 
MAIN INCUBATION TIMES 
Main incubation QC I QC Il QC III 
time (minutes) concentrations nmol/L 
A 30 0·5 3·8 10·9 
B 60 3.9 6.6 18.2 
C 90 4.8 9.9 22.0 
".~ : .. ~. '1'--::, . ~~k:;:,~al ues 2.3 11.0 21.3 
\ :~/!,<~,,~~';:';',\ ';"'-. ~ 
TABLE IX VALUES FOR COMMERCIAL QUALITY CONTROL MATERIAL 
WHEN ASSAYED FOR A VARYING PREINCUBATION TIME 
Preincubation time QC I QC II QC lIT 
minutes concentrations nmol/L 
15 4.5 10.1 19.0 
30 4.3 10.5 20.1 
45 5.0 11.8 35 
60 8.5 12.5 44 
6.2.3 MAIN INCUBATION TIME 
Standard and QC tubes were set up as described in 
Section 6.2.2. All tubes were incubated with 100 pL of 
antibody for 30 minutes prior to the main incubation for 
A 30, B 60 and C 90 minutes at room temperature. 
Results The resulting calibration curves are shown in 
Figure 11, as spline fits, and values for the quality 
controls in TablelXS Although the 30 minute incubation 
gives a good steep curve at low concentration it plateaus 
at around 200 pg/0.1 mL (26 nmol/L for plasma). The 
incubation for 90 minutes produces a good curve with a 
difference of 0.7 absorbance units between the bottom and 
top standards. The quality control results show the 90 
minute incubation to give results closest to those 
obtained by RIA. The 90 minute main incubation was 
therefore used in subsequent experiments. 
6.3 REVISED GENERAL ASSAY PROCEDURE 
Standards (0 to 400 pg/0.1 mL) were prepared as in 
Section 2.4.2 and QC's and patients extracted as in 
Section 2.9 in duplicate. After drying off the solvents 
all tubes had additions made as follows with incubations 
at a room temperature of 18 - 20 ·C. 
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Figure 11 
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Vortexed and incubated for 20 minutes 
Vortexeo and 
Vortexed and 
\ + 100 pL 170HP-HRP 
incubated for 90 minutes 
l
Oncu'bat+ed500 pL DAMP-R (1 mg) 
for 5 minutes 
, 
Vortexed and incubated for further 10 minutes 
Transferred to mlgnetic rack for 5 minutes 
I 
t Supernatants decanted 
, 
1 mL PBS/triton-X added and vortexed 
Transferred to magnetic rack for 5 minutes 
Supernatants decanted 
+ 2 mL OPD 
Vo rtexed and 
o , 
Incubated for 1 hour in the dark 
Allowed to 
Absorbance 
+ 600 pL 4M hydrochloric 
J 
acid 
stand on magnetic rack for 10 minutes 
I 
of all tubes read at 492 nm. 
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6.4. E. EVALUATION OF THE ASSAY 
6.4.1 SPECIFICITY OF THE ASSAY 
An indication of the specificity of the assay 
procedure for measuring 170HP in the presence of other 
naturally occurring steroids was assessed in the following 
manner. 
1 mg/mL solutions of cortisol, testosterone, 
progesterone, and dehydroepiandrosterone (DHA) were 
prepared in absolute ethanol as detailed in Section 
2.4.3. Cross reactivities are often expressed as a 
percentage by comparing the mass of competing steroid 
required to decrease the binding on the standard curve by 
50% as suggested by Abraham (1969). Another way of 
expressing this cross-reactivity is to measure the 
apparent 170HP in the presence of competing steroids at 
the limits of their normal occurrence in plasma and at 
multiples of this upper limit. To achieve this aim 
varying volumes of the prepared ethanolic solutions were 
pipetted into glass assay tubes and dried down in the 
vacuum oven prior to assay by the established procedure. 
The reference ranges for these 4 competing steroids were 
taken as: 
cortisol 9am 150 - 700 nmol/L 
testosterone female o - 2.8 nmol/L 
male 8 - 27 nmol/L 
progesterone peak greater than 40 nmol/L 
DHA female 700 - 4860 nmol/L 
male 700 - 2780 nmol/L 
Results are listed in Table X 
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TABLE X CROSS-REACTION OF COMPETING STEROIDS IN THE 
170HP ASSAY 
Steroid Equivalent Multiple of top ~7easured 
conc in of reference 170HP 
assay tube range nmol/L 
nmol/L female male 
cortisol 5400 7.7 7.4 
2700 3.9 5.6 
1350 1.9 1.8 
625 0.9 0.4 
testosterone 42 1 5 1.6 6.6 
33 12 1.2 0.9 
25 9 0.9 0.5 
17 6 0.6 0.2 
8 3 0.3 0.2 
progesterone 200 5 36.5 
100 2.5 24.0 
50 1.3 11.9 
25 0.6 11.4 
DHA 7000 1.4 2.5 9.6 
3500 0.7 1.3 5.8 
1750 0.4 0.6 3.1 
875 0.2 0.3 1.6 
At levels of cortisol seen in normal individuals or 
even patients with Cushing's Disease having moderately 
raised cortisols up to around 1400 nmol/L would only 
contribute about 2 nmol/L to the 170HP measured. Only in 
the more severe Cushing's Syndrome, with adrenal tumours 
and ectopic ACTH secreting tumours would the 170HP be 
significantly affected. 
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In the case of testostercne, levels less than 33 
nmol/L would contribute only about 1 nmol/L of 170HP. Only 
at levels above 33 nmol/L is the cross reactivity 
high. Thus in all women and in the ma~ority of men 
testosterone would have little effect. 
Progesterone, which is released from the corpus 
with 
day 
by a 
luteum post ovulation, gives high cross-reaction 
this antibody. Progesterone rises to a peak at around 
21 of the menstrual cycle and is also accompanied 
peak of 170HP. The normally accepted peak level of 13 
nmol/L for 170HP would have to be reassessed using this 
assay. Although this cross-reaction could be a prcblem in 
the 170HP assay in pubertal girls and in women, since 
only small amounts of progesterone are synthesised in the 
adrenals this interference would be negligible for males 
and prepubertal girls. 
DHA was also seen to oross-react giving an apparent 
170HP of about 6 nmol/L at DHA's normal circulating 
levels. 
The assay using this antibody would appear to be 
most suitable for measuring 170HP in pre-pubertal 
child ren. 
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6.5 
6.5.1 
PRECISION 
STANDARD CURVE 
As the intensity of colour development depends partly 
on the room temperature and age of the reagents, for a 
comparison of the standard 
calculation was used: 
Absorbance of standard 
curves 
Absorbance of zero standard 
the following 
X 100 
The arithmetic mean of this result was calculated 
for each standard point and these were plotted against 
the mass of the standard (Figure 12)" 
deviation indicated. 
6.5.2 ASSAY 
6.5.2.1 INTRA-BATCH PRECISION 
A number of plasma specimens and qualjty controls 
which had been previously assayed by RIA were extracted 
and assayed using the procedure described in Section 6.3. 
TABLE XI INTRA-BATCH PRECISION 
Concentration 
by RIA 
(nmol/L) 
1.5 
2.5 
12.0 
12.2 
13 .2 
294 
number of 
repljcates 
12 
1 1 
10 
10 
10 
10 
mean 
3.8 
4.1 
11.7 
16.1 
12.8 
226 
The overall precision was poor. 
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standard 
devjatjon 
1 .0 
0.7 
1.9 
3.4 
3.5 
34.4 
Coefficjent 
of 
Varjation 
25.3 
16.2 
16.0 
21.3 
27 .1 
15.2 
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Figure 12 Replicate standard curve from 8 batches 
showing 1 standard deviation of each standard point 
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6.5.2.2 INTER BATCH PRECISION 
Commercial quality control material, at 2 dose 
levels, was included in each assay batch following the 
procedure of Chapter 6.3. 
Results are shown in Table XII together with the target 
values and the values obtained by the RIA procedure. As 
can be seen the precision of the EIA was better than the 
RIA at low concentration and of the same order at the 
higher concentration. 
TABLE XII INTERASSAY 
COMPARING EIA WITH RIA 
ErA 
number 
mean 
standard deviation 
coefficient of 
variation 
RH 
number 
mean 
standard deviation 
coefficient of 
variation 
PRECISION AT 2 DOSE I,EVELS 
Level Level 2 
7 
4.73 
0.58 
12.3 
20 
2·34 
0.62 
26.6 
8 
11 .01 
1. 58 
14.4 
20 
11 .0 
1.27 
11.6 
6.6 ACCURACY OF THE ASSAY 
6.6.1 COMPARISON OF RESULTS OBTAINED BY EIA AND RIA 
25 pL plasma spedmens and 200 )1L saliva samples 
were extracted as described in Section 2.9. The EIA was 
then carried out as described in Section 6.3. 
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Results were compared with those previously obtained by 
RIA (Section 2.10.1) and are shown as a scattergram in 
Figure 13 for plasma and Figure 14 for saliva. For the 
plasma samples the correlation coefficient was good at 
0.963 but with a small pos i ti ve bi as as shown by the 
regression line of y = 0.984x + 0.94, however there were 
only 15 results and all of the concentrations were less 
than 20 nmol/L. For the salivas the correlation 
coefficient was again good at 0.936 with only a very 
small positive bias as shown by the regression line of 
y = 1.165x + 0.128. From these limited results the 
potential of the EIA for clinical use looked promising. 
6.6.2 PLASMA DILUTION CURVES 
6 plasma samples with concentrations of 170HP varying 
from 10 to 35 nmol/L were serially diluted with PES, 
extracted and assayed by EIA. 
Results The effective volume of neat plasma taken was 
then plotted against the measured 170HP concentration to 
give Figure 15. Whilst the 3 neat samples having 
concentrations of 20 nmol/L and above diluted well to give 
lines passing close to the origin of the graph the 3 
samples having a neat concentration of 17 nmol/L and below 
would extend to give a negative concentration at high 
dilution suggesting that the lower end of the standard 
curve was less precise. In the clinical situation plasma 
levels less than 10 nmol/L hold little significance 
however, with the low concentrations found in the saliva 
of treated congenital adrenal hyperplasia patients this 
insecurity at the lower limit of the assay needs to be 
borne in mind. 
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At this point in the project it was necessary to look 
at the viability of using other commercially available 
antibodies as the one in use to date was rapidly coming 
to an end and the manufacturer was unable to supply 
further vials of the same bleed. To minimise on costs of 
the assay reagents only 3 new anti bod i es were investi gated 
which could all be obtained at a discount to the NHS. 
6.7 COMPARISON OF STANDARD CURVES OBTAINED WITH 
THREE DIFFERENT ANTIBODIES TO 170HP 
Using 
Section 6.3 
the standard assay procedure 
the Steranti antibody used 
described in 
to date was 
compared with a recommended 
antibody from Steranti and a 
dilution of new rabbit 
sheep anti-170HP obtained 
from Guildhay Antisera, University of Surrey, UK. In the 
case of the latter antibody DAMP-S, which was 
magnetisable particles bound to donkey anti-sheep 
antibody was used in place of the DAMP-R. OPD was the 
chromogen used in the colour development stage of the 
ErA. 
Results As can be seen from Figure 16 compared to the 
curve obtained with the original Steranti 
the new antibody from the same supplier 
antibody both 
and. the sheep 
anti-170HP serum from Guildhay gave very poor standard 
curves. 
It was decided at this stage to change the chromogen 
used in the assay of the HRP activity from OPD to TMB 
since the latter had been shown to be non-carcinogenic and 
non-mutagenic by Bos et al (1981). 
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Figure 16 Comparison of standard curves obtained 
with 3 different antibodies to 170HP 
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6.8. INVESTIGATION OF THE CONCENTRATION OF NEW ANTIBODY 
PREPARATIONS REQUIRED TO GIVE A WORKABLE STANDARD CURVE. 
To determine if a suitable standard curve could be 
obtained by using the new Steranti antibody, or the 
Guildhay antibody at a higher concentration than that 
recommended zero and 400 pg/O.l mL 170HP standards were 
incubated with the in 20000 dilution of 170HP-HRP and 
100 pL aliquots of various concentrations of the neat 
antibody equivalent to 10, 5, 2.5, 1.25 
the recommended concentrations. 
and 0.63 times 
The results are shown in TABLE XIII. 
TABLE XIII. ABSORBANCES FOR HIGH AND LOW STANDARDS WITH 
NEW STERANTI ANTIBODY AND GUILDHAY ANTIBODY AT VARIOUS 
CONCENTRATIONS USING TMB AS CHROMOGEN 
Concentration of 
antibody relative 
to that recommended 
X 10 
X 5 
X 2.5 
X 1. 25 
X 0.63 
A B S 0 R BAN C E at 450 nm 
Steranti (New) Guildhay 
rabbit anti-170HP sheep anti-170HP 
o pg 400 pg o pg 400 pg 
2.73 0.97 >3.00 2.50 
1.43 0.44 2.72 1.00 
0.70 0.17 1 .29 0.26 
0.40 0.11 1.06 0.16 
0.23 0.10 0.78 0.12 
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Comparing these absorbances with Tlffi as chromogen 
with those in Figure 16 where OPD was used it can be seen 
that the use of the TMB enhances the difference in 
absorbance between the zero and 400 pg standard. However 
even with this improvement in absorbances it would 
require a concentration of around 5 times that 
recommended to obtain a difference of 1 absorbance unit 
between the highest and lowest standard concentration. 
However the recommended concentration of the Guildhay 
antibody would appear to be acceptable. Unfortunately 
continued work with this antibody in the tritium RIA gave 
a poor standard curve and since it was thought desirable 
to use the same antiserum for both the RIA and EIA a 
different supply of antibody was sought. 
A rabbit antibody to 170HP supplied by Bio-Clinical 
Services Ltd became available at this time. Ps this was 
the same antibody as that used by Walker et al (1979) for 
assay of 170HP in saliva at the Tenovus Institute in 
Cardiff the possibility of using this preparation in the 
RIA and EIA was investigated. This antibody gave an 
acceptable curve with the RIA at the recommended 
dilution. 
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6.9 DETERMINATION OF INCUBATION TIMES FOR 170HP 
ASSAY WITH CARDIFF ANTIBODY PREPARATION 
6.9.1 VARIABLE PRE-INCUBATION TIME WITH ANTIBODY 
100 rL aliquots of standard solutions of 170HP in 
absolute ethanol (0 - 1600 pg/0.1mL) were dried down in 
the vacuum oven to give 4 sets of standards. 
At 15 
, 
minute intervals 
+ 100 pL working antibody 
to a set of tubes 
At 1 hour after addition to first set of tubes 
I + 100 pL 170HP-HRP addec to all 
f tubes 
Vortexed ana incubated further 2 hours 
at room temperature 
The reaction was then concluded as described in 
Chapter 2.11. 
Results The standard curves obtained at each of the 
pre-incubation times are shown in Figure 17. As there was 
little difference between each of the curves 30 minutes 
was chosen to minimise assay time whilst allowing 
sufficient time for addition of reagents to large 
numbers of assay tubes to reduce drift in the results. 
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Figure 17 Variable pre-incubation time with working 
solution of Cardiff 170HP antibody 
1.2 
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0.2 
0.0 
o 400 800 
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1200 1600 
6.9.2 VARIABLE MAIN INCUBATION TIME 
The procedure described above was repeated using a 
pre-incubation time of 30 minutes and main incubation time 
of 30, 60 and 120 minutes. Also a patient's specimen 
having a 170HP of 48 nmol/L, as assayed by RIA, was double 
diluted with PBS to give values of 24 and 12 nmol/L. 
25 uL aliquots of each of these specimens together 
with a sample having a value of 2 nmol/L were extracted 
with diethyl ether and treated as in Chapter 2.9. The 
reaction was then concluded as described in Chapter 2.11. 
Results The curves obtained are shown in Figure 18 and the 
results for the unknowns in Table XIV. 
TABLE XIV VALUES OBTAINED FOR THE SPECIMENS WITH A 
PRE-INCUBATION TIME OF 30 MINUTES AND VARIABLE MAIN 
INCUBATION TIME 
mA 
2 
12 
24 
48 
Main 
30 
170HP 
0.2 
24 
28 
45 
incubation time (minutes) 
60 120 
concentration (nmol/L) 
0.2 0.2 
6.1 0.2 
23·4 8.2 
52.8 17.6 
For each of the jncubation times the low 170HP 
concentration was undetectable but for the diluted 
specimen a main incubation time of 60 minutes gave 
measured 170HP levels close to those obtained by RIA. 
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Figure 18 Variable main incubation time after 
pre-incubation time of 30 minutes 
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6.10 GENERAL ASSAY PROCEDURE FOR USE WITH CARDIFF RABBIT 
ANTI-170HP ANTIBODY 
Standards (0 to 1600 pg/O.l mL) were prepared as in 
Section 2.4.2 and QC's and patients extracted as in 
Section 2.9 in duplicate. After drying off the solvents 
all tubes had additions made as follows with incubations 
at a room temperature of 18 - 20 ·C. 
25 pL 
100 pL standards (0 - 1600 pg) 
OC's/patients plasma (Extracted as in Section 2.9) I + 100 pL antiserum 
Vortexed and incubated for 30 minutes I + 100 pL 170HP-HRP 
Vortexed and incubated for 60 minutes I + 500 pL DAMP-R (1 mg) 
Vortexed and incubated for 5 minutes 
I Transferred to magnetic rack for 5 minutes 
I Supernatants decanted I ,+ 2 mL TMB 
Incubated for 15 minutes with multi-vortexing 
every 5 minutes I + 500 pL 4M hydrochloric acid 
Allowed to stand on magnetic rack for 5 minutes I " 
·Absorbance of all tubes read at 450 nm within 
1 hour. 
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6.11 
6.11.1 
EVALUATION OF THE ASSAY 
SPECIFICITY OF THE ASSAY 
The procedure detailed in Chapter 6.4.1 was carried 
out using a stock solution of 20 ng of steroid per 100 pL 
of ethanol. This solution was double diluted to give a 
series of 9 solutions down to 80 pg/O .1 mL. 100 pL 
alIquots of these solutions were then dried down in assay 
tubes in a vacuum oven prior to carrying out the EIA. 
Cortisol, corticosterone, dehydroepiandrosterone sulphate, 
dehydroepiandrosterone, 11-deoxycortisol, androstenedione, 
prednisolone, dexamethasone, testosterone, and 
progesterone were the steroids tested. 
Results are shown in Table XV adopting the Jlbraham 
(1969) format. Of the steroids tested only progesterone 
and ll-deoxycortisol gave cross-reactions greater than 1%. 
The effect of this would be that a progesterone of 50 
nmol/L, which might be seen 7 days post ovulation, would 
give a value for 170HP of 13.2 nmol/L in the EIA. This 
compares with the value of 11.2 nmol/L obtained with the 
original Steranti antibody (Section 6.4.1). Also a DHA of 
5000 nmol/L, around the upper limit of the reference 
range for women, would give a 170HP level of 9.6 nmol/L. 
However a plasma cortisol of 1300 nmol/l, testosterone of 
14 nmol/L, and androstenedione of 13 nmol/L would all 
give apparent 170HP of less than 
the corticosteroids cortisol, 
nmol/L. 
prednisolone 
Since 
and 
dexamethasone are all used in replacement therapy of 
patients diagnosed as having 21 OHase deficiency the low 
cross-reactivity with each of these 
particularly important. 
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preparations is 
TABLE XV CROSS-REACTIVITY OF VARIOUS STEROIDS IN THE 
EIA USING BIO-CLINICAL SERVICES A~TIBODY 
Steroids 
170HP 
cortisol 
corticosterone 
dehydroepiandrosterone 
% Crcss-reactivity at 170HP 
label binding inhibition 
of 50% 
100 
~ 0.3 
"::0.1 
L. 0.3 
dehydroepiandrosterone sulphate <' 0.3 
1.3 11-deoxycortisol 
testosterone 
and rostened ione 
progesterone 
prednisolone 
dexamethasone 
6.12 
6.12.1 
PRECISION 
STANDARD CURVE 
<0.1 
~ 0.3 
10.2 
L. 0.1 
<' 0.1 
The ratio of absorbance of standard to absorbance of 
the zero standard was calculated as in Chapter 6.5.1 for 
each standard in each of 9 batches. The arithmetic means 
were calculated for each of the standards. Figure 19 
shows a plot of the means with + 1 
-. 
indicated. 
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Figure 19 Replicate standard curve from 9 botches 
of extraction assay showing 1 standard deviation of 
each standard point 
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6.12.2 ASSAY 
6.12.2.1 INTRA-BATCH PRECISION 
12 aliquots each of 3 patient's sera having 170HP 
concentrations of 11, 20 and 32 nmol/L, as measured by 
RIA, were assayed in the same batch. 
The results are listed Table XVI. JI cceptable 
coefficients of variation were obtained and were an 
improvement on those obtained 
antiserum, Table XI above. 
TABLE XVI INTRA-BATCH PRECISION 
mean standard deviation 
11.9 1.56 
20.1 2.22 
33.3 2.64 
with 
% 
the E'teranti 
coefficient of 
variation 
13 .1 
11.1 
7.9 
A similar exercise using the RIA with the same 
antibody gave a coefficient of variation of 21.0% at the 
20 nmol/L level and 5.9% at 32 nmol/l 
6.12.2.2 INTER-BATCH PRECISION 
Commercial quality control material at 3 dose levels 
were included in the assay batch. These were frcm a 
different manufacturer to those used in Chapter 6.5.2.2. 
Results are shown in Table XVII with comparative RIA 
data. 
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TABLE XVII INTERASSAY PRECISION AT 3 DOSE LEVELS 
COMPARING EIA WITH RIA 
ErA 
Level Level 2 Level 3 
number 6 6 6 
mean 4.3 14.6 34.2 
standard deviation 0.61 2.78 5.13 
coefficient of 14.1 19.1 15.0 
variation 
RrA 
number 10 8 8 
mean 5.2 12.7 25.6 
standard deviation 0.9 2.55 3.36 
coefficient of 16.8 20.0 13 .1 
variation 
6.13 ACCURACY OF THE ASSAY 
6.13.1 COMPARISON OF RESULTS OBTAINED BY EIA AND RIA 
USING THE SAME RABBIT ANTI-170HP ANTIBODY 
25fL plasma specimens and 200 pL saliva samples were 
extracted as described in Section 2.9. The ElA was then 
carried out as described in Section 6.10. 
Results The levels of 170HP measured by ElA were 
compared with those obtained in the RIA and are shown in 
Figure 20 for plasma and Figure 21 for saliva samples. A 
correlation coefficient of 0.949 was obtained for both 
comparisons showing goocl agreement however the intercept 
of + 128 for the salivas showed a marked positive bias 
when using the ElA. 
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Figure 20 
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6.13.2 COMPARISON OF RESULTS OBTAINED BY EIA 
NATIONAL EXTERNAL QUALITY ASSURANCE SCHEME 
WITH 
Specimens of serum are regularly distributed by the 
National External Quality Assurance Scheme for assay by 
participating Clinical Chemistry laboratories. The 
specimens consist of pools, some of which are spiked with 
pure 170HP obtained from Sigma Chemical Company, UK and 
some of which contain only endogenous steroid. 25 FL of 
each specimen was extracted as described in Section 2.9 
and the ErA carried out as described in Section 6.10. The 
results of the EIA were plotted 
laboratory trimmed mean (ALTM). This 
the mean of the results from all 
against the all 
is derived by taking 
the laboratories for 
each of the pools and excluding any values more than 3 
standard deviations from that mean. The truncated mean 
is then calculated to give the ALTM. 
Results Figure 22 shows the comparison of EIA results 
versus the ALTM. The correlation coefficient of 0.947 was 
good. Considering that the ALTM was derived from a number 
of laboratories using widely different immunoassays the 
overall comparison was good and would suggest that the 
method be adequate for the reliable diagnosis of 210Hase 
deficiency. 
6.13.3 PLASMA DILUTION CURVES 
6 plasma samples with concentrations of 170HP ranging 
from 28 to 130 nmol/L were serially diluted with PBS, 
extracted and assayed by EIA. 
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Figure 22 Comparison of 170HP concentrations in plasma 
measured by EIA versus National External Quality Assurance Scheme 
o 25 50 75 100 
170HP nmol/L NEQAS ALTM 
Results: Figure 23 shows the effective volume of plasma 
used plotted against the measured 170HP. The specimen 
having an initial concentration of 130 nmol/L did not 
dilute linearly suggesting that other steroid metabolites 
may have been present in the sample. The other specimens 
diluted well and the curves intercept the axes close to 
zero. 
6.13.4 RECOVERY OF ADDED STEROID 
500 pL of various of the working 170HP standards in 
ethanol was added to assay tubes and dried down in the 
vacuum oven. 500 pL of several plasmas were added to the 
assay tubes and vortex mixed for 30 seconds. At 15 minute 
intervals for 2 hours all the tubes were vortexed for 20 
seconds to redissol ve the 170HP in the plasma. 25 pL 
aliquots of each sample were then extracted and assayed 
in duplicate by the EIA. 
The results are shown in Table YVIII 
TABLE XVIII RECOVERY OF ADDED 170HP 
Endogenous Added Calculated 170HP by Recovery of 
170HP 170HP new 170HP EIA added 170HP 
pg pg pg pg % 
48 12.5 60.5 66 109 
116 25 141 145 103 
173 50 223 216 97 
214 25 239 245 103 
214 100 314 297 95 
430 100 530 488 92 
567 200 767 710 93 
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Figure 23 Plasma dilution curves uSing 
Cardiff antibody 
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The recoveries varied from 92 to 109% This limited 
data would suggest that the method is underestimating at 
the higher concentrations. 
6.14 SENSITIVITY 
The sensitivity of the assay was assessed by 
extracting and assaying 20 aliquots of a sample previously 
found to have an undetectable 170HP level. The mean and 
standard deviation of the absorbances was calculated. The 
sensitivity was then found by reading off the standard 
curve the mass of 170HP equivalent to the mean absorbance 
minus 2 standard deviations of the absorbance. This gave a 
sensitivity of 0.94 nmol/L which is greater than the 
0.4 nmol/L achieved with the RIA but probably reflects the 
difficulty in measuring the high absorbances of the low 
standards. 
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CHAPTER 7 
APPLICATIONS OF EXTRACTION EIA 
7.1 INTRODUCTION 
The diagnosis of CAH due to 21-hydroxylase deficiency 
relies on the measurement of 170HP in blood and since 
this is usually performed by RIA it is often limited to 
specialised laboratories in large hospitals. The aim of 
this project has been to develop an EIA requiring a 
minimum of equipment so making the assay possible to 
perform in a District General Hospital. 
Following diagnosis either in the neonate or in the 
older child monitoring of the corticosteroid replacement 
therapy is required on a regular basis to avoid under or 
over treatment both of which can result in eventual 
stature. To collect blood can be traumatic both for 
short 
the 
child and the clinician. The collection of saliva has the 
advantage of being a non-invasive technique so allowing 
frequent sampling. It also allows for the study of the 
effects on endogenous steroid levels of a change in dosage 
and type of medication. 
7.2 COMPARISON OF 170HP CONCENTRATIONS IN SALIVA 
VERSUS PLASJU. 
Ideally 50 paired samples, covering a wide 
concentration range, would be required to look at the 
relationship between levels of 170HP in saliva and 
plasma. However this was not possible to achieve because 
of ethical considerations. 
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In the early stages of the use of salivary 170HP for 
monitoring the treatment of CAH patients 11 paired 
samples of blood and saliva were collected from children 
attending an outpatient clinic for non-endocrine 
conditions and a further 6 paired samples from CAH 
patients. 
Samples were extracted as detailed in Section 2.10 
and assayed using RIA with 
antiserum. Although no EIA 
results are shown to illustrate 
the 2 types of specimen. 
the 
data 
the 
original Steranti 
is available the RIA 
relationship between 
Results are shown in Figure 24. At low concentrations 
the comparison between salivary 170HP and plasma levels 
was poor with plasma values of less than 5 nmol/L having 
saliva values ranging from 100 - 300 pmol/L. However at 
concentrations above 6 nmol/L the comparison 
acceptable based on this limited study. 
CLINICAL PARAMETERS 
GROWTH VELOCITY 
Patients attended monthly clinics after 
was 
initial 
diagnosis and at between 3 and 6 month intervals when 
under reasonable control. Height velocities were 
calculated from the result of supine length of children 
up to 3 years of age or height measurements in older 
children, performed at least 6 months apart. Results were 
plotted on a height velocity chart to compare with 
expected values. 
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Figure 24 
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7.3.2 BONE AGE 
At intervals of 12 months the patient had an X-ray of 
the wrist performed. The relative development of 20 bones 
were then assessed by the Consultant Paediatrician and the 
20 Bone Maturity Score calculated by the Tanner 
Whitehouse method. 
7.4 USE OF THE EXTRACTION EIA IN STUDIES OF 
CHILDREN WITH CAH 
7.4.1 PLASMA 
The diurnal rhythm of 170HP synthesis was studied on 
a 6 year old boy who presented with CAH. He had been 
referred by his general practitioner with a height 
greater than the 97th percentile and early development of 
puberty. He was admitted to the ward and had blood 
samples collected over a 24 hour period. 
Results Figure 25 shows the exaggerated circadian rhythm 
of 170HP in this boy and highlights the need to be careful 
in the interpretation of a single result. Usually the 
blood sample would be taken during the working day when, 
in this patient's case the level was greater than 100 
nmol/L. However at midnight the 170HP concentration was 25 
nmol/L which is only about twice the upper limit of the 
reference range. It could be expected that some 
individuals might have an apparently normal level in the 
evening. 
SALIVA 
The EIA was used to measure 170HP in saliva from 
children regularly attending the Endocrine Clinic. 
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Figure 25 Plasma 170HP concentrations throughout 
24 hour period in an untreated boy with 
non salt-losing CAH 
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7.4.2.1 TWO-DAY CONSECUTIVE SALIVARY 170HP PROFILES 
As the collection of saliva was easy for the patient 
consecutive 2 day profiles were routinely performed to 
ensure that any noted trend was consistent and not due to 
situations arising on an individual day. 
Figure 26 shows the results of 2 day profiles in 3 
children found to be under good control based on the 
clinical parameters. In each case the patients were being 
treated with hydrocortisone taken before breakfast, before 
lunch and at bedtime. The graphs illustrate the marked 
diurnal variation in 170HP concentrations and the 
reproducibility of results obtained on consecutive days. 
Such data collection would be difficult to achieve using 
blood sample collection. 
7.4.3 INDIVIDUAL RESPONSE TO THERAPY 
The frequent sampling of the saliva permits the study 
of responses of individuals to replacement therapy. 
FIRST MONTH OF LIFE 
A baby girl who presented with ambiguous genitalia 
at bi rth, was diagnosed as 
deficiency based on a plasma 
Initially her electrolytes were 
having 
170HP of 
within 
21-hydroxylase 
130 nmol/L. 
the reference 
range for a neonate but on day 8 she had a salt losing 
mmol/L (reference crisis with a plasma sodium 
range 132 - 142 mmol/L) and a 
(3.5 - 5.6) 
133 
of 129 
potassium of 6.8 mmol/L 
Figure 26 Two-day consecutive salivary 170HP profiles 
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Salivas were collected in the morning and 
results are shown in Figure 27. The initial 
concentration was high at 100,000 pmol/L but this 
the 
170HP 
fell 
rapidly over the 3 days of monitoring. The stress of the 
salt losing crisis resulted in a rapid elevation of 170HP. 
On restoration of the electrolytes to normal levels by the 
administration of 9_alpha-fludrocortisone the 170HP 
concentrations decreased to less than 1500 pmol/Lby the 
20th day of life. 
FIRST YEAR OF LIFE 
The baby girl whose data is shown in Figure 28 was 
noted to have ambiguous genitalia at birth. Chromosome 
analysis showed the baby to be a genetic female and a 
concentration of 400 nmol/L of 170HP in blood resulted in 
a diagnosis of 21-hydroxylase deficiency. By the end of 
the first week her sodium had fallen to 118 mmol/L with a 
potassium of 7.1 mmol/L. She was treated with 
9_alpha_fludrocortisone and hydrocortisone in divided 
doses. A cosage of the latter ranging from 23 to 28 mg per 
square meter body surface area per day was maintained 
throughout her first year. 
Initially salivary 170HP exceeded 39,000 pmol/L. By 
one month of age there was a. considerable variation 
throughout the day ranging from 
morning to around 5000 pmol/L at 
times. 
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Figure 27 Salivary morning 170HP concentrations 
in· a newly diagnosed girl in the first month of life 
100000 
80000 
60000 
40000 
20000 
o 5 
SALT LOSING 
CRISIS 
10 15 20 
Chronological age (days) 
25 30 
Figure 28 
22500 
+ 
20000 
17500 
.. 
-< 15000 
'" 
(5 
--.J E 
:: 12500 
:c 
0 
r-
~ 10000 
0 
.2: 
c; 
V> 7500 
5000 ~ 
2500 
0 
0 1 
Salivary 170HP concentrations in a girl 
with CAH in the first year of life 
+ + 
+ 
)( 
.. 
)( )( 
.. • it 
2 3 4 5 6 7 8 9 10 
Chronological age (months) 
+++++ Morning )()()()()( Noon 
....... Evening 
* 
11 12 
There was a gradual decline in mjdday and evening 
concentrations so that by the 5 months these levels were 
below 1400 pmol/L whereas the morning values were still 
markedly elevated. It was not until the baby was 9 months 
old, that the morning level approached 1100 pmol/L. 
This case illustrates the importance of monitoring 
the 170RP throughout the day as measurement of the morning 
170RP only would have suggested the patient was being 
undertreated whereas the other 2 timed levels indicate 
adequate treatment. If the patient had been monitored on 
only a morning plasma 170RP level taken in the outpatient 
clinic this would also have lead to a misleading result. 
7.4.3·3 
THERAPY 
SALIVARY PROFILES ON CHANGE OF REPLACEMENT 
The monitoring of change of therapy is easier with 
salivary measurements and allows fine tuning of the 
medication. A boy who was diagnosed as having salt-losing 
CAR at another hospital had been treated with cortisone 
acetate at a dosage of 10 mg morning and evening. Figure 
29 traces the salivary profiles from 8.6 to 12.2 years of 
age on this therapy. The 170RP was determined using the 
RIA procedure. 
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Figure 29 Salivary 170HP concentrations in a boy 
treated with cortisone acetate for 5 years 
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From chronological age 8.6 years to 10.7 years all 
salivary 170HP levels were maintained below 600 pmol/L 
for each of the daily collections. The bone age 
determination at age 9.2 years showed a delay of 0.6 
years and 10.7 years this delay had increased to almost a 
year showing that the treatment was adequate to keep his 
growth in check and allow for the maximum eventual height 
to be gained from the growth spurt of puberty. 
For the next year the salivary 170HP profile 
showed a rapidly increasing evening level with 
concentrations greater than 4000 pmol/L. 
The replacement corticosteroids were then changed to 
2mg of prednisolone taken morning and evening. 
shows the 170HP concentrations as measured 
extraction EIA. 170HP concentrations at age 12.7 
Figure 
by 
to 
30 
the 
13.2 
years were low with the bone age at 14.2 years showing an 
increase in delay to 1.2 years. The prednisolone dosage 
was reduced to 2 mg in the morning and mg at night. 
Salivary 170HP levels for the following year reflect the 
increased levels of circulating corticosteroids 
in increased growth. The bone age determined at 
years reflected this with a fall in the delay 
development to 0.6 years. 
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Figure.30 Salivary 170HP concentrations in a boy 
following change to prednisolone replacement therapy 
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CHAPTER 8 
RAPID DIRECT ASSAY 
8.1 INTRODUCTION 
The extraction as so far developed has been shown to 
correlate well with the RIA and to be useful for 
monitoring replacement therapy for CAH, however there is 
a need for a rapid 170HP assay for the diagnosis of the 
condition which can be carried out directly on plasma. 
Ideally this assay should meet the following criteria:-
. a) it should be easy to perform with a minimal number 
of stages. 
b) equipment should be limited to that found in any 
routine clinical chemistry laboratory 
c) the incubation temperatures should be such that 
they can be consistently maintained in any climate 
d) reagents should be stable and require minimal 
preparation 
e) the sample size should be small 
f) a qualitative assay should give a clear 
distinction between normal and abnormal results. 
8.2 
8.2.1 
COMPONENTS OF THE ASSAY 
REAGENTS 
These were as used for the extraction EIA using 
Bio-Clinical Services antibody and TMB as chromogen. 
Solutions for the standard curve were prepared as 
described in Section 2.4.2 but using PBS instead of 
ethanol when diluting the stock 170HP solution. The 
standard was found to be stable in buffer for only a week 
necessitating a fresh dilution to be made in PBS 
for each assay. A 1 in 30,000 dilution of 170HP-HRP was 
used. 
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8.2.2 
PLASMA. 
DISPLACEMENT OF 170HP FROM BINDING PROTEINS IN 
As endogenous steroids are largely bound to proteins 
in the blood plasma (Section 1.8.1) it was necessary to 
include a blocking agent to displace the 170HP from 
corticosteroid binding protein and albumin. Section 3.3.5 
showed that merthiolate and ANS both inhibited the HRP 
activity even at a mass of 0.02 mg/tube and that the least 
inhibitory effect was found with sodium salicylate where 2 
mg/assay tube could be used with only a 19% reduction in 
absorbance. El-Gamal (1988) found 5 13 mg sodium 
salicylate/tube to be adequate as a displacing agent using 
100 ¥L of plasma in a fluoroimmunoassay for 170HP. For 
initial studies of incubation conditions 2mg/tube of 
salicylate was used in this direct assay. 
8.2.3 INITIAL ASSAY PROCEDURE 
The conditions established for the extraction assay 
(Section 6.10) were used as follows. 
Standards 
100 pL 
25 ~L 
I 
170HP standard 
PBS/BSA 
l 
Patients 
100 ¥L PBS/BSA 
25 ~L plasma 
I 
+ 100 yL 2% sodium salicylate 
+ 100 pL antibody 
All tubes were vortex mixed and 
incubated for 30 minutes at 18° - 22°C 
, + 100 pL 170HP-HRP 
All tubes were vortex mixed and 
incubated for 60 minutes at 18° - 22°C 
The assay was then continued as for the extraction assay 
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8.3 EFFECT OF INCLUSION OF STEROID FREE PLASMA ON 
THE STANDARD CURVE. 
Steroid free plasma (SFP) was prepared by a 
modification of the method of Barlow (1979) incubating the 
charcoal/agar with the plasma pool for 4 hours, with 
frequent agitation, before centrifugation. An assay was 
set up as described in Section 8.2.3 with inclusion of 25 
pL of SFP instead of PBS/BSA in the standard tubes. For 
comparison a number of plasma samples from children of 
various ages were also included. Non-specific binding 
(NSB) tubes were set up using 100 pL PBS/BSA in place of 
the antibody in tubes containing zero standard. 
Results The NSB tubes had absorbances of 0.07 in the 
presence of SFP. The two standard curves are shown in 
Figure 31 using a spline fit. There was enhanced 
absorbance at each standard point in the presence of SFP 
compared with tubes containing only buffer. 
The absorbances for the children's specimens were 
read against each of the standard curves and the 
corresponding results are shown in Table XIX. The 
reference range of 170HP in children is up to 10 nmol/L 
using the RIA reference method. None of the children were 
suffering from endocrine disorders. The values obtained 
for these children's specimens were closer to the 
reference range when using the standard curve not 
containing SFP. 
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Figure 31 Effect of inclusion of steroid free plasma 
in the standard curve for the direct assay 
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TAl3LE XIX COMPARISON OF RESULTS OBTAINED AGAINST A 
STANDARD CURVE A) CONTAINING SFP AND B) WITHOUT SFP. 
Patient Standard curve prepared· 
Sex Age with SFP without SFP 
M/F years 170HP nmol/L 170HP nmol/L 
F 4 87 29 
F 5 38 12 
F 5 26 6.8 
F 5 34 10.8 
M 9 60 19.9 
F 2/12 107 28.5 
M 7 21.7 5.1 
F 9 54 18.3 
F 13 53 18.0 
M 6 21.7 5.7 
F 9 34.8 10.8 
F 16 61.6 21.1 
8.4 INVESTIGATION OF INCUBATION CONDITIONS 
A total assay time of under 2 hours would be 
desirable with an incubation temperature of 37° to allow 
use of the assay in different countries with varying 
ambient temperatures. To this end the effect of 
incubating at 37°C with a pre-incubation with antibody of 
10 minutes and a main incubation of 5, 10, 20, 30, 50 or 
60 minutes was investigated. Because of the large number 
of assay tubes involved only the zero and 1600 pg 170HP 
standards were used. 
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Since the assay was primarily intended as a 
diagnostic test for neonates, where often only very 
small volumes of blood are available and the haematocrit 
is high, the use of 10 pL of sample was investigated. 
Also to test the effect of other protein matrices in the 
assay human serum albumin (RSA) and a child's specimen 
with a low 170RP concentration were used. 
The assay was set up as described in Section 8.2.3. 
TABLE XX ABSORBANCES 
INCUBATION TIMES AND 
FOR STANDARDS WITH VARYING 
IN THE PRESENCE OF HUJoV,N SERUM 
ALBUMIN AND A CHILD' S PLASMA 
Time 
minutes 
5 
10 
15 
20 
30 
50 
60 
5 
10 
15 
20 
30 
50 
60 
A B 
PBS/BSA 
only 
0.93 
1.17 
1 .21 
1.30 
1.24 
1.42 
1.49 
S 0 R BAN C E AT 
50 g/L RSA 
ZERO STANDARD 
0.91 
1.10 
1 .14 
1.30 
1.10 
1.41 
1.49 
1600 pg 170HP 
0.32 0.31 
0.41 
0.40 
0.53 
0.50 
0.68 
0.83 
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0.40 
0.42 
0.56 
0.49 
0.64 
0.75 
450 nm 
Chi Id's 
plasma 
0.94 
1.14 
1.11 
1.28 
1.16 
1.40 
1.55 
0·35 
0.45 
0.44 
0.54 
0.52 
0.73 
0.71 
Results are shown in Table XX. A main incubation time 
of 20 minutes at 37°C gave a similar absorbance for HSA, 
child's plasma 
concentrations. 
or PBS/BSA for both 
As HSA is expensive and any plasma 
standard 
pool is 
potentially hazardous, in terms of hepatitis or human 
immunodeficiency virus, incubation conditions were further 
investigated using just the PBS/ESA. 
8.5 
SALICYLATE 
EFFECT OF VARYING CONCENTRATIONS OF SODIUM 
The displacing action of various concentrations of 
sodium salicylate was investigated using SFP, a sample 
previously assayed by the extraction assay and found to 
1 ::::d:~~u1:~:P th: f pr::~du::O~~L se:::on P:~~~:~ '~1,i~:J~~~:fil"~ 
The results are presented in Table XXI: 
TABLE XXI EFFECT OF VARYING CONCENTRATIONS OF SODIUM 
SALICYLATE AS A DISPLACING AGENT 
Mass of sod ium PBS/BSA SFP High 
salicylate/tube 170HP 
mg ABSORBANCE AT 450 NM 
0 0.94 0.49 0.29 
0.5 1.37 1.49 0.38 
1.0 1. 34 1.46 0.34 
2.0 1.33 1.37 0.31 
3.0 1.30 1.40 0.30 
4.0 1. 32 1.41 0.31 
5.0 1.31 1.37 0.30 
10.0 1. 21 1.34 0.29 
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The tubes containing zero sodium salicylate gave the 
least absorbances for each of the samples. However the 
effect of increasing concentrations of salicylate on the 
displacement of 170HP from the binding proteins is 
difficult to gauge since the salicylate also inhibits the 
peroxidase activity. A mass of 2 mg/tube was chosen for 
future experiments based on the findings of EI-Gamal 
et al (1988). 
8.6 ASSAY PROCEDURE FOR DIRECT ASSAY 
The total assay time was reduced to 2 hours using the 
following procedure: 
100 pL standards 
10 fL
1 
PBS/RSA 
100 pL PBS/BSA 
10 pL ,Plasma 
+ 100 pL 2% sodium salicylate 
+ 100 pL antibody 
All tubes vortexed and incubated 10 minutes 
at 37°C in a water bath 
, + 100 pL 170HP-HRP 
All tubes vortexed and incubated 20 minutes 
at 37°C in a water bath 
All tubes removed from water bath and allowed to cool 
for 1 minute at room temperature 
, + 500 pL DAMP-R 
All tubes vortexed and incubated for 5 minutes at 
room temperature 
Tubes transferred to rack and placed on magnet 
for 2 minutes 
Supernatants decanted 
, + 1 mL PBS + 0.1% triton-X 
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Tubes vortexed and stood on magnet for 5 minutes 
Supernatants decanted and tubes left upturned with ends 
on paper towels for 10 minutes to allow thorough draining 
after which large droplets were removed with a cotton 
wool wad. 
+ 2 mL TMB/substrate 
Incubated for 10 minutes at room temperature with 
vortex mixing after 5 minutes 
l Qualitative visual assessment of colour compared with 
standards was possible at this stage 
\ + 500 pL 4M hydrochloric acid 
Tubes allowed to stand on magnet for 5 minutes 
Absorbance of all tubes measured at 450 nm. 
EVALUATION OF DIRECT ASSAY 
PRECISION 
STANDARD CURVE 
The absorbance of standard versus the absorbance of 
the zero standard was calculated as in Section 6.5.1 for 
each standard in each of 8 batches. Figure 32 is a plot 
of the mean for each standard point plotted against the 
standard concentration and showing 1 standard deviation 
either side of each point. The curve fit used was a spline 
plot. 
8.7.1.2 INTRA-EATCH PRECISION 
10 aliquots each of 6 patient's sera were assayed in 
the same batch. 
The results are listed in Table XXII. 
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Figure 32 
showing 1 
o 
Replicate standard curve from 8 batches 
standard. deviation of each standard point 
for the direct assay 
400 800 
170HP pg 
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1200 1600 
TABLE XXII INTRA-BATCH PRECISION 
Mean standard % Coefficient 
Concentration deviation of variation 
nmol/L 
2.9 1. 53 52.7 
5.2 2.42 46.6 
8.2 2·32 28.4 
12.4 3.36 27.1 
44.2 11 .73 26.6 
66.0 8.24 12.5 
The coefficients of variation were poor and only 
acceptable at the highest concentration tested. This 
imprecision was probably due to the shortened incubation 
times with substrate. 
As there is a rapid increase in colour 
development in the first few minutes of the reaction (see 
Figure 4) reagents must be added to each of the tubes at 
the same rate even so there is a time delay between 
addition to the first and last tubes such that the first 
tube might be incubated for up to a minute longer 
representing a 10 - 20% time difference depending on the 
addition step. At higher concentrations of 170HP the 
absorbance is lower and the timing less critical. In the 
development of the assay the size of the batch was often 
60 - 80 tubes. In routine use batch sizes of 20 tubes 
would be more normal and it could be expected that the 
time delays would be much smaller so the precision should 
improve. 
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8.7.1.3 INTER-BATCH PRECISION 
3 patient's specimens were assayed in each of 10 
batches and the results are shown in Table XXIII. 
TABLE XXIII INTER-BATCH PRECISION FOR DIRECT ASSAY 
mean nmol/L 
standard deviation 
% coefficient 
of variation 
Patient 
6.2 
3.7 
60.0 
Results The overall precision was 
Patient 
2 
20.7 
9.6 
46.4 
poor 
be partly due to varying incubation times 
batch. 
8.7.1.4 ACCURACY OF THE ASSAY 
8.7.1.4.1 COMPARISON OF RESULTS OBTAINED 
AND EXTRACTION EIA 
27 specimens were assayed by the 
but 
from 
BY 
Patient 
3 
53.2 
12.2 
22.9 
may again 
batch to 
DIRECT EIA 
direct and 
extraction methods. The results were compared and are 
shown as a scattergram in Figure 33. The correlation 
coefficient was 0.79 showing a poorer comparison between 
these assays on individual specimens although the overall 
trend is the same. 
A further 8 specimens from jaundiced neo~ates on the 
Special Care Baby Unit were assayed by both met}ods. 
The results, ljsted jn Table XXIV, had very high 
apparent 170HP concentrations using the direct assay but 
had more 'normal' levels when measured on the extraction 
method. Any abnormal results obtained on the current 
direct assay WOU10 require confirmation cn the extraction 
assay. 
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Figure 33 
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TABLE :XXIV 170HP CONCENTRATIONS FROM JAUNDICED NEONATES 
AS DETERMINED BY DIRECT AND EXTRACTION ASSAYS 
Age Direct Extraction 
days 170HP 170HP 
nmol/L nmol/L 
480 35.4 
4 142 27.0 
6 330 13.9 
11 242 15.3 
11 208 4.1 
17 260 21.4 
20 82 18.1 
30 179 24.2 
8.7.1.4.2 COMPARISON OF RESULTS WITH NEQAS 
5 NEQAS samples having concentrations of endogenous 
hormone ranging from 14.6 to 68.8 nmol/L as assessed by 
the ALTM's were assayed by both the direct assay and the 
extraction assay. The results are shown in Table XXV. 
TABLE:XXV COMPARISON OF NEQAS SAMPLES MEASURED BY DIRECT 
AND EXTRACTION EIA'S 
ALTM Direct Extraction 
nmol/L nmol/L nmol/L 
14.6 13 .1 24.5 
37.5 30.8 46.2 
48.7 40.0 53.1 
57.8 53.7 62.1 
68.8 56.4 83.2 
All specimens contained endogenous 170HP only. 
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On this limited selection of NEQAS samples the 
comparison was good with the direct assay giving results 
closer to the ALTM than the extraction assay. 
8.8 EFFECT OF VARYING PROGESTERONE LEVELS ON 
APPARENT 170HP CONCENTRATIONS MEASURED 
In the studies in Section 6.11.1 on the specificity 
of the antibody it was noted that the cross-reaction with 
progesterone was 10.2%. To investigate this effect in the 
direct procedure a series of specimens, with varying 
progesterone levels were assayed for 170HP. 
The results are listed in Table XXVI. 
TAllLE XXVI EFFECT OF PROGESTERONE ON MEASURED 170HP 
CONCENTRATIONS. 
Progesterone 
concentration 
nmol/L 
1.5 
2.8 
4.4 
31.3 
51. 5 
57.2 
84.3 
125.6 
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170HP 
concentration 
nmol/L 
6.7 
6.8 
11.3 
49.5 
54.5 
51.5 
136.1 
193.2 
The interpretation of this aata is complicated since 
the peak progesterone level in women 7 days after 
ovulation is also associated with a 170HP peak 
time. However since the reference range for the 
using an extraction assay, peaks at 12 nmol/L 
levels of 170HP noted in this study are 
at this 
latter, 
the high 
probably 
contributed to by cross-reaction of progesterone and other 
steroid metabolites with the antibody. 
8.9 PLASMA DILUTION CURVES 
7 plasma samples were diluted with SFP and assayed as 
in Section 8.6. 
Results The effective volume of neat plasma taken was 
plotted against the measured 170HP concentration for each 
of the specimens to form Figure 34. All of the samples 
diluted linearly with 5 of the lines almost passing 
through zero. 
8.10 SENSITIVITY OF THE ASSAY 
The sensitivity of the direct assay was assessed by 
assaying 25 aliquots of SFP. The 
deviation of the absorbances was 
mean and standard 
calculated. The 
sensitivity was then found by reading off the standard 
curve the mass of 170HP equivalent to the mean absorbance 
minus 2 standard deviations of the absorbance. This gave a 
sensitivity of 4 nmol/L which is acceptable for a 
screening assay. 
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Figure 34 Plasma dilution curves 
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8.11 REFERENCE RANGES 
106 specimens from children of various ages, who 
had attended Paediatric Out-Patient Clinics 
non-endocrine conditions were assayed by the 
for 
direct 
assay. The results were grouped and 
concentrations (m), standard deviations 
the 
(sd) 
mean 
and 
reference range calculated as the mean + 2 standard 
deviations. 
The results are shown in Table XXVII. 
TAllLE :XXVII REFERENCE RANGES FOR CHILDREN 
Premature Non- Boys & Girls 
jaundiced jaund iced Up to 2 
babies babies years 
n 9 8 10 
m 185 17.6 18.0 
sd 98 8.7 11.9 
reference range Up to 380 Up to 35 Up to 42 
Girls Girls Boys 
2 - 10 10 - 16 2 - 16 
years years years 
n 40 16 25 
m 6.8 14.8 7.8 
sd 4.5 13.6 6.2 
reference range Up to 15.8 Up to 42 Up to 20.2 
All 170HP concentrations are in nmol/L 
The ranges calculated from this limited number of 
samples would suggest that this direct assay could be used 
for screening for CAH where concentrations of 170HP in 
excess of 100 nmol/L would be expected in children with 
210Hase deficiency. 
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Only in the case of the premature :aunciceo babies 
would an equivocal result be expected and these samples 
could be re-assayed on an extraction assay or a further 
sample obtained a few days later when the jaundice had 
resolved. 
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CHAPTER 9 
DISCUSSION 
Congenital adrenal hyperplasia due to 210Hase 
deficiency in a child is a condition which, once 
recognised, is relatively easy to treat with steroid 
replacement therapy and with suitable monitoring can 
result in a normal life expectancy together with normal 
stature. Untreated the condition may result in a small 
adult or even be life-threatening in patients with the 
salt losing form. 
Whilst a number of methods have been described for 
measuring 170HP concentrations in plasma and saliva these 
have been largely based on isotopic immunoassays requiring 
both expertise in the handling of the isotopes and 
specialised instrumentation for monitoring the signal 
together with expensive refrigerated centrifuges for the 
separation step. 
The aim of this project has been to develop methods 
for the measurement of 170HP in plasma and saliva 
involving cheap reagents with low hazards in handling and 
requiring only readily available laboratory 
instrumentation. 
In preparing for the immunoassay the assay of 
peroxidase was studied in detail together with its 
stability at the working dilution. In the first part of 
the project OPD was used as the chromogen as this was the 
one most commonly used in published immunoassays using 
HRP as the enzyme label. However this suffered from the 
disadvantage of being carcinogenic requiring care in 
preparation and use. 
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Solutions of OPD were not stable and required 
preparation from the solid immediately prior to the 
assay. The colour development was slow and and needed 
incubation times of approximately an hour in order to 
achieve maximal intensity although the use of triton-X, as 
suggested by Porstmann (1981), 
absorbance. 
did enhance the 
TMB was used later and this was shown to achieve 
similar levels cf absorbance in only 15 to 20 minutes with 
a blue colour which could be assessed visually in 
comparison with the absorbance of the standards. Again the 
inclusion of triton-X enhanced the colour development and 
the addition of acid, to stop the reaction, resulted in a 
yellow product ef almost twice the absorbance. Also the 
TMB had been shown by Bos et al (1981) to be 
non-carcinogenic. Stock solutions of the chromogen could 
be prepared in dimethylsulphoxide and these were shown to 
be stable for at least a year when stored at room 
temperature in the dark. A further observation was that 
the absorbance could be monitored at wavelengths of 450 
and 405 nm with the latter being used when the absorbance 
at 450 nm exceeded 2 absorbance units. The colour 
development reaction could be terminated by the use of 4M 
hydrochloric acid instead of 2M sulphuric acid. This 
overcame the problem of addition of sulphuric acid to 
the ferric oxide magnetisable particles which results 
in evolution of hydrogen sulphide. Bos had suggested 
the use of 4M hydrochloric acid resulted in 
non-specific oxidation of the product but this was 
that 
rapid 
not 
found to be the case using the concentration of 
peroxide as determined in this project together 
triton-X. 
hydrogen 
with the 
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The working solution of TJVJJl needed to be prepared and 
used within a couple of hours but this only involved 2 
liquid additions to the prepared buffer. 
The commercial availability of the carboxymethyloxime 
of 170HP simplified the preparation of the steroid enzyme 
conjugate and the acid anhydride reaction was achieved by 
the use of simple equipment which could be constructed in 
any chemistry laboratory. The purity of the product was 
difficult to assess since it was not possible to separate 
the unreacted peroxidase enzyme from the conjugated 
product as the molecular weights were similar, however 
the washing step in the immunoassay 
separation. 
would achieve this 
Although a number of attempts at the conjugation were 
necessary to ensure a low temperature throughout the 
incubation the eventual yield was sufficient 170HP-HRP for 
at least 300,000 assay tubes for a total cost of reagents 
of less than £100. The equipment as described could 
easily accommodate a tripling in the volumes of reagents 
for the production of 170HP-HRP sufficient for 1,000,000 
assay tubes. 
The use of magnetisable particles linked to second 
antibody for the separation of free and bound fractions of 
the immunoassay helped minimise the total incubation 
times. Because of the necessity to wash the bound fraction 
prior to the colour development stage of the assay the 
traditional use a centrifuge can add up to 15 minutes to 
the assay time whereas with the use of magnetisable 
particles a complete wash and sedimentation stage can be 
carried out in under 5 minutes. 
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The DAMP-R and -8 as supplied by Serono Diagnostics 
was found to be stable for at least 4 years and the 
reagent should be widely applicable to other assays. The 
addition of triton-X to the wash buffer ensured rapid 
draining after the supernatant had been discarded. 
The 8teranti antibody which was used initially in the 
extraction assay gave a good standard curve for both the 
EIA and RIA. A pre-incubation with antibody resulted in a 
larger drop in absorbance at low concentration and a main 
incubation time of go minutes gave results similar to the 
RIA for the quality control material tested. The 
immunoassay took about 3 hours in addition to the 
extraction procedure. Only progesterone gave serious 
interference in the assay such that it would be most 
suitable for measuring 170HP concentrations in 
pre-pubertal girls, and in boys and men. 
~Then the 8teranti antibody became unobtainable 3 new 
antibodies were investigated. Whilst one of these was 
shown to give an acceptable difference in absorbance for 
the zero and top standard in the EIA this antibody was 
re~ected since it did not perform adequately in the RIA. 
On reflection it may have been advisable to have sought 
the best antibody available for each individual assay even 
if that had resulted in the use of 2 different suppliers 
and an increase in costs. 
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The incubation conditions for the EIA were 
investigated using the TMB as chromogen. This enabled the 
time of colour development to be reduced and the whole 
jmmunoassay could then be performed in approximately 2.5 
hours, in addition to the extraction stage, compared with 
the 3 hours needed to perform the RIA. 
Again the specificity of the antibody was good except 
for the 10.2% cross-reaction with progesterone. Tntra- and 
inter-batch precjsion was comparable with that found for 
the RIA. The comparison of results obtained for the EIA 
versus the RIA was good for both plasma and saliva 
that in the latter case there was a positive bias. 
would limit the use of the assay for monitoring 
except 
This 
of 
overtreatment of children on replacement therapy. The 
comparison with results for plasma 170HP concentrations 
with other laboratories through the NEQAS scheme was 
good. 
The use of saliva for measuring 170HP in monitoring 
the treatment of CAR proved popular with the patients as 
it saved the trauma of having blood collected in the 
clinic and also allowed samples to be collected throughout 
the day to allow fine tunjng of the replacement therapy. 
Also collection and assay of samples between clinic 
appointments enabled results to be available at the same 
time as the clinical parameters of growth velocity and 
bone age. The mothers of small infants did encounter some 
difficulties initially but by patience and using the 
cotton wool wad they were soon able to oollect adequate 
speojmens. 
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Using the technique of saliva collection it has been 
possible to obtain detailed profiles of 170HP 
concentrations in relation to the effect of various 
glucocorticoid preparations. In the young developing child 
hydrocortisone in divided doses can mimic the diurnal 
variation seen in normal individuals. The technique can 
easily be used to distinguish adequate treatment from both 
under and over-treatment to ensure maximal growth. In the 
older child the use of prednisolone has been studied and 
this taken as a single dose is often adequate in adult 
life. 
The direct assay was developed using only 10 pL of 
plasma which would allow the assay to be carried out on a 
capillary sample collected from a heel prick. It was 
difficult to show the effectiveness of the sodium 
salicylate in displacing the 170HP from the binding 
proteins because of the inhibitory effect of the 
salicylate on the peroxidase, however this blocking agent 
has been used at this concentration in isotopic assays. 
Incubation at 37°C accelerates the reaction and also 
enables a consistent temperature to be maintained 
irrespective of the ambient temperature. The total assay 
time was around 2 hours. Whilst the tubes were vortex 
mixed vigorous shaking of the tubes could achieve the 
same effect. The only equipment, therefore, required is a 
precise adjustable pipettor and preferably a dispenser 
for the TMB/hydrogen peroxide. 
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The colour development is rapid and the intensity of 
the blue colour is sufficient for estimating the 
concentration of the unknown by comparing the colour with 
that of the standards by eye. After terminating the colour 
development with acid the absorbance of the tubes can be 
measured on a simple spectrophotometer. Relatively cheap 
instruments are beccming available which can be used to 
measure the absorbance simultaneously at 2 wavelengths. 
This type of photometer could be used to measure the 
absorbance of the yellow product at 450 and 405 nm. Often 
software is available on board the instrument for 
performing a curve fit and calculating concentrations of 
the unknowns. 
Both inter- and intra-batch precision was poor but 
would be acceptable if the assay was only used as a 
screening test for CAR. Further development work on the 
assay is required to improve the precision. 
Although the reference range data was limited it 
would suggest that the assay would be suitable to 
distinguish between normal levels of 170RP and those of 
greater than 100 nmol/L seen in affected children with 
CAR. The problem of high 170RP levels in premature babies 
was also eluded to by Cacciari et al (1983) who found high 
.levels in infants born before 37 weeks gestation. l·~urphy 
et al (1983) also found high levels in ill pre-term 
infants. The high levels by the direct assay were 
considerably lower 
method suggesting 
when re-assayed 
cross-reaction with 
by the extraction 
the antibody by 
steroid precursors probably as a result of impaired 
metabclism by the immature liver in these patients. 
9.1 FURTHER POSSIBLE DEVELOPMENTS FOR THE ASSAYS 
It would certainly be worthwhile looking at different 
170RP antibodies now available to determine if a low 
cross-reaction with progesterone could be achieved since 
this aspect severely limits the use of the present 
described assays to the investigation .of children. The 
late onset form of CAR may present in women at the 
infertility clinic when high levels of progesterone may 
also be found in the luteal phase of the menstrual cycle. 
A rapid direct assay would be useful for screening these 
patients. Monoclonal antibodies are becoming available 
and it may be possible to increase the specificity of the 
assay by the use of one of these. 
One of the original reasons for choosing RRP as the 
enzyme label was that it can 
chemiluminescence and fluorescence 
be assayed by 
in addition to the 
colorimetric methods investigated here. A short study was 
carried out using chemiluminescence and a manual 
luminometer kindly loaned by Packard Instruments. This 
gave only poor results, which have not been reported, but 
if an automated luminometer were available this could be 
further investigated. 
The acid anhydride conjugation reaction has been 
widely used for the preparation of steroid-enzyme labels 
and could be utilised to develop similar methods for other 
steroids, such as cortisol, testosterone and 
androstenedione, and also use the same magnetisable 
particle separation and colour development stages. 
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To further simplify the assay procedure the use of 
dropper type bottles could be investigated for addition 
of the antibody and conjugate reagents vlhich would only 
require preparation once a month. By incorporating the 
hydrogen peroxide into the sodium acetate buffer this 
would then only require the addition of an aliquot of 
stock TMB at the time of the assay. In this way a "kit" 
could be prepared which could be used by peripheral 
laboratories. The overall stability would need to be 
investigated to determine the shelf-life. It would also 
be useful to see if a simple extraction with diethyl 
ether prior to re~assay with the rapid assay would be 
sufficient to reduce the problem of high steroid levels 
found in premature infants. 
Other workers have used blood spots in place of 
saliva and the use of the rapid assay could be 
investigated after eluting the 170HP into assay buffer. 
Although the intention throughout has been to 
minimise on required equipment, for larger centres 
screening for CAH the use of automated sample handling 
systems could be investigated which would be expected to 
improve the precision of the assay and reduce the "drift" 
seen in large batches. 
9.2 OVERALL CONCLUSION 
Methods for measuring 170HP have been described 
which, with further refinements, could have wide 
applications in clinical laboratories involved in the 
study of CAH both for diagnosis and treatment. 
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